<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001987.pub2" GROUP_ID="PROSTATE" ID="437099092909415053" MERGED_FROM="" MODIFIED="2008-06-10 16:45:47 +0200" MODIFIED_BY="Jim Tacklind" NOTES="&lt;p&gt;Title changed from benign prostatic hyperplasia to obstruction: 4-25-2003&lt;/p&gt;" NOTES_MODIFIED="2008-06-10 09:43:23 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="RH01" REVMAN_SUB_VERSION="5.0.12" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.3">
<COVER_SHEET MODIFIED="2008-06-10 16:45:47 +0200" MODIFIED_BY="Jim Tacklind">
<TITLE>Laser prostatectomy for benign prostatic obstruction</TITLE>
<CONTACT MODIFIED="2008-06-10 16:45:47 +0200" MODIFIED_BY="Jim Tacklind"><PERSON ID="16066" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hoffman</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Staff Physician</POSITION><EMAIL_1>rhoffman@unm.edu</EMAIL_1><ADDRESS><DEPARTMENT>General Internal Medicine 111GIM</DEPARTMENT><ORGANISATION>New Mexico VA Health Care System</ORGANISATION><ADDRESS_1>1501 San Pedro Drive SE</ADDRESS_1><CITY>Albuquerque</CITY><ZIP>87108</ZIP><REGION>New Mexico</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 505 256 2727</PHONE_1><FAX_1>+1 505 256 2888</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-06-10 16:45:47 +0200" MODIFIED_BY="Jim Tacklind"><PERSON ID="16066" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hoffman</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Staff Physician</POSITION><EMAIL_1>rhoffman@unm.edu</EMAIL_1><ADDRESS><DEPARTMENT>General Internal Medicine 111GIM</DEPARTMENT><ORGANISATION>New Mexico VA Health Care System</ORGANISATION><ADDRESS_1>1501 San Pedro Drive SE</ADDRESS_1><CITY>Albuquerque</CITY><ZIP>87108</ZIP><REGION>New Mexico</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 505 256 2727</PHONE_1><FAX_1>+1 505 256 2888</FAX_1></ADDRESS></PERSON><PERSON ID="9180" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Roderick</FIRST_NAME><LAST_NAME>MacDonald</LAST_NAME><SUFFIX>MS</SUFFIX><POSITION>RGC, Prostatic Diseases and Urologic Cancers Group</POSITION><EMAIL_1>roderick.macdonald@med.va.gov</EMAIL_1><ADDRESS><DEPARTMENT>General Internal Medicine  (111-0)</DEPARTMENT><ORGANISATION>VAMC</ORGANISATION><ADDRESS_1>One Veterans Drive</ADDRESS_1><CITY>Minneapolis</CITY><ZIP>55417</ZIP><REGION>MN</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 612 467 1666</PHONE_1><FAX_1>+1 612 725 2284</FAX_1></ADDRESS></PERSON><PERSON ID="9186" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Timothy</FIRST_NAME><LAST_NAME>Wilt</LAST_NAME><POSITION>Co-ordinating Editor, Prostatic Diseases and Urologic Cancers Group</POSITION><EMAIL_1>Tim.Wilt@med.va.gov</EMAIL_1><ADDRESS><DEPARTMENT>General Internal Medicine (111-0)</DEPARTMENT><ORGANISATION>VAMC</ORGANISATION><ADDRESS_1>One Veterans Drive</ADDRESS_1><CITY>Minneapolis</CITY><ZIP>55417</ZIP><REGION>Minnesota</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 612 467 2681</PHONE_1><FAX_1>+1 612 467 2118</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-02 10:36:01 -0500" MODIFIED_BY="Jim Tacklind">
<UP_TO_DATE>
<DATE DAY="29" MONTH="9" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="9" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="11" YEAR="2003"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="2" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="29" MONTH="9" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Minneapolis/VISN-13 Center for Chronic Diseases Outcomes Research (CCDOR)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Dept. of Veterans Affairs Health Services Research and Development Program</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medicine Department, New Mexico VA Health Care System, Albuquerque, New Mexico</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-10 09:43:23 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-06-10 09:43:23 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-09 10:43:39 -0500" MODIFIED_BY="[Empty name]">Laser prostatectomy for benign prostatic obstruction</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-10 09:43:23 -0500" MODIFIED_BY="[Empty name]">
<P>Bothersome lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) is a common problem for older men.  LUTS can be both irritative (urgency, frequency, frequent nighttime urinations) and obstructive (weak stream, hesitancy, intermittency, and feeling the bladder is not emptied).  Transurethral resection of the prostate (TURP) is considered the gold standard treatment for symptomatic BPO.  TURP improves urinary symptoms and urinary flow by surgically removing prostatic tissue through the urethra.  However, side effects occurring in approximately 20% of all TURPs include blood loss requiring transfusion, infections, strictures, sexual dysfunction, urinary incontinence, and urinary retention.  Laser prostatectomy, which uses a laser to destroy the enlarged prostate tissue that leads to LUTS, is a minimally invasive procedure currently used as an alternative to TURP.  This review of 20 studies involving 1898 subjects found laser techniques to be useful and relatively safe alternatives to TURP.  The small number of enrolled subjects and differences in study design limit any definitive conclusions regarding which type of laser technique is the most effective.  Improvements in LUTS and urine flow slightly favored TURP, though laser procedures had fewer side effects and shorter hospitalization times.  The follow-up durations of these studies ranged from 6 to 36 months and men with extremely large prostates were generally excluded from the trials. The risk of needing a reoperation for recurrent LUTS was higher following laser procedures. Study results were insufficient to adequately compare laser techniques with other minimally invasive procedures. More studies, using randomized treatment assignment, enrolling larger numbers of subjects, and comprehensive measures of treatment effectiveness and side events, are needed to better define the long-term safety and durability of laser techniques for treating LUTS associated BPO.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-02 10:47:06 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Symptomatic benign prostatic obstruction is a common problem for older men. The gold standard treatment, transurethral resection of the prostate (TURP), significantly improves urinary symptoms and urinary flow. However, TURP has up to a 20% morbidity. Currently, there are a number of minimally invasive procedures that may be safe, effective alternatives to TURP. One promising surgical technique is laser prostatectomy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the therapeutic efficacy and safety of laser prostatectomy techniques for treating men with symptomatic benign prostatic obstruction.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomized controlled trials were identified from the Cochrane Collaboration Library, MEDLINE, EMBASE, bibliographies of retrieved articles and reviews, and contacting expert relevant trialists and laser manufacturers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials evaluating laser prostatectomy treatment for men with symptomatic BPH. Trials were eligible if they (1) were randomized comparisons of a laser technique with TURP, (2) included at least 10 men with BPO in each treatment arm, (3) provided at least 6-months follow-up, and (4) included clinical outcomes such as urologic symptom scales or urodynamic measurements. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data extraction and assessment of methodologic quality was performed independently by two reviewers. Information on study design, subject and treatment characteristics, adverse events, urinary symptoms, and urinary flow were extracted using a standard form. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-06-02 10:47:06 -0500" MODIFIED_BY="[Empty name]">
<P>Twenty studies involving 1898 subjects were evaluated, including 4 studies with multiple comparisons. We found eight comparisons of TURP with contact lasers, eight with non-contact lasers, four with hybrid techniques, and one with interstitial laser coagulation (ILC). Two studies compared transurethral electrovaporization (TUVP) with contact lasers, one study compared interstitial laser coagulation with transurethral microwave thermotherapy (TUMT), and one study compared holmium contact lasers (HoLRP) with open prostatectomy. Among the studies comparing laser prostatectomy with TURP, follow-up duration ranged from 6 to 36 months. Mean age (67.2 yrs), mean baseline symptom score (20.2), and mean baseline peak urinary flow (9.2 mL/s) did not differ by treatment group. The pooled percentage improvements for mean urinary symptoms ranged from 59% to 68% with lasers and 63% to 77% with TURP. The improvements for mean peak urinary flow ranged from 56% to 119% with lasers and 96% to 127% with TURP. Overall, laser subjects were less likely to receive transfusions or develop strictures and their hospitalizations were shorter. Non-contact laser subjects were more likely to have dysuria, urinary tract infection, and retention. Re-operation occurred more often following laser procedures.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Laser techniques are a useful alternative to TURP for treating BPO. Small sample sizes and differences in study design limit any definitive conclusions regarding the preferred type of laser technique. Data were insufficient to compare laser techniques with other minimally invasive procedures. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-02 13:20:04 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Lower urinary tract symptoms (LUTS) consistent with benign prostatic obstruction (BPO) become increasingly prevalent with age. LUTS can be both irritative (urgency, frequency, nocturia) and obstructive (weak stream, hesitancy, intermittency, and incomplete emptying). By age 80, an estimated one in four men will have undergone treatment to relieve LUTS related to BPH (<LINK REF="REF-Barry-1990" TYPE="REFERENCE">Barry 1990</LINK>). For many years, the transurethral resection of the prostate (TURP) has been the definitive treatment for BPO. Approximately 400,000 procedures are performed annually at a total cost of $5 billion (<LINK REF="REF-Oesterling-1995" TYPE="REFERENCE">Oesterling 1995</LINK>). Although TURP has been proven to reduce symptoms of BPO and increase urinary flow compared with watchful waiting (<LINK REF="REF-Wasson-1995" TYPE="REFERENCE">Wasson 1995</LINK>), the procedure has some limitations. The morbidity of TURP is nearly 20%, including blood loss requiring transfusion, infections, strictures, sexual dysfunction, urinary incontinence, urinary retention, and the development of the transurethral resection syndrome (<LINK REF="REF-Oesterling-1995" TYPE="REFERENCE">Oesterling 1995</LINK>; <LINK REF="REF-McConnell-1994" TYPE="REFERENCE">McConnell 1994</LINK>; <LINK REF="REF-AUA-2003" TYPE="REFERENCE">AUA 2003</LINK>). Furthermore, up to 25% of patients undergoing TURP do not have satisfactory results (Lepor, 1990), and the reoperation rates is about 1% to 2% annually (<LINK REF="REF-Wasson-1995" TYPE="REFERENCE">Wasson 1995</LINK>; <LINK REF="REF-Roos-1998" TYPE="REFERENCE">Roos 1998</LINK>).</P>
<P>In recent years a number of minimally invasive surgical techniques have been developed for treating BPH, including transurethral incision of the prostate, prostatic stents, microwave therapy, and laser prostatectomy (<LINK REF="REF-Lepor-1996" TYPE="REFERENCE">Lepor 1996</LINK>; <LINK REF="REF-Jepsen-1998" TYPE="REFERENCE">Jepsen 1998</LINK>; <LINK REF="REF-Tewari-1999" TYPE="REFERENCE">Tewari 1999</LINK>; <LINK REF="REF-Oesterling-1995" TYPE="REFERENCE">Oesterling 1995</LINK>). The laser techniques include visual laser ablation of the prostate, contact laser ablation, interstitial laser, transurethral evaporation of the prostate, and transurethral ultrasonic laser incision. There has been considerable interest in laser prostatectomies because preliminary data suggest that they are effective and safe treatments for BPO. Compared to TURP, laser procedures have been reported to have fewer complications, require shorter hospitalizations, and can be performed on outpatients (<LINK REF="REF-Oesterling-1995" TYPE="REFERENCE">Oesterling 1995</LINK>). However, the different laser techniques may not be comparable in efficacy, comparisons with other minimally invasive procedures are limited, and few long-term follow-up data are available. Finally, no systematic reviews and quantitative meta-analyses of these techniques have been published to evaluate safety and efficacy. Primary care physicians are increasingly becoming responsible for managing symptomatic BPO patients with behavioral and drug therapies. However, when patients are considering surgical interventions, primary care physicians should also be able to inform them of the risks and benefits of the various procedures. </P>
</BACKGROUND>
<OBJECTIVES>
<P>Our objective was to conduct a systematic review and, where possible, quantitative meta-analysis, of randomized controlled trials to evaluate the efficacy and safety of laser prostatectomy techniques compared to TURP in treating men with symptomatic BPO. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-02 10:50:08 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-06-02 10:40:20 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized controlled trials of at least 6 months duration with or without blinding. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Men with symptomatic BPO as determined by urinary symptoms or scale scores with or without documented decreased urinary flow rates.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Laser prostatectomy techniques reviewed included visual laser ablation of the prostate (VLAP), contact laser ablation, interstitial laser, and transurethral ultrasonic laser incision (TULIP), and transurethral evaporation of the prostate. Control interventions could include transurethral resection of the prostate (TURP), open prostatectomy, transurethral incision of the prostate (TUIP), transurethral electrovaporization of the prostate (TUVP), pharmacologic therapy, watchful waiting, electrovaporization of the prostate, prostate stents, radiofrequency transurethral needle ablation, microwave therapies, or high-intensity focused ultrasound. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-02 10:40:20 -0500" MODIFIED_BY="[Empty name]">
<P>The primary clinical outcome was the efficacy of laser prostatectomy in improving urinary tract symptoms based on changes in urologic symptom scale scores (American Urologic Association (AUA) Symptom Index, International Prostate Symptom Score (IPSS), Madsen-Iversen, Boyarsky). Secondary outcomes included changes in peak and mean urinary flow. Data were recorded for 6- and/or 12-month follow-up periods. We also extracted data on operative time, hospital length of stay, catheter duration, the need for re-hospitalization or re-operation, adverse events, and perioperative mortality.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-02 10:49:35 -0500" MODIFIED_BY="[Empty name]">
<P>We searched MEDLINE from 1966 through June 2002 using an optimally sensitive search strategy from the Cochrane Collaboration with the MeSH headings: prostatic hypertrophy, prostatectomy, prostatic hyperplasia/surgery, laser surgery, TULIP, and ELAP (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). We also searched the Cochrane Library, the Prostatic Diseases and Urologic Cancers Group registry, Science Citation Index, and reference lists of all identified trials and previous reviews. The <I>Journal of Urology</I> and <I>Urology</I> were hand-searched from 1998 through June 2002. There were no language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-02 10:50:08 -0500" MODIFIED_BY="[Empty name]">
<P>Titles and abstracts of the electronic search results were evaluated by two independent reviewers. From the results of the electronic searches, bibliography searches, hand searches, and contacts with experts and manufacturers, two reviewers independently selected trials meeting previously defined inclusion criteria. Trials selected by at least one reviewer were retrieved. Two reviewers independently abstracted study characteristics and outcomes, including information on study design, subject characteristics, interventions, follow up, treatment outcomes, and adverse events. Differences were resolved by discussion among the reviewers or using an independent arbitrator. Reasons for study exclusion were documented.</P>
<P>Methodologic quality was assessed based on selection bias (randomization strategies), performance bias (whether those receiving care were blinded), detection bias (whether outcomes assessors were blinded to assigned therapy), attrition bias (systematic differences between groups in losses to follow-up), clinical description of study subjects, baseline comparison of study groups, duration of follow-up, discussion of co-interventions, completeness of efficacy and morbidity data. As a measure of overall methodologic study quality we will assess the quality of concealment of treatment allocation according to a scale developed by Schulz (<LINK REF="REF-Schulz--1995" TYPE="REFERENCE">Schulz 1995</LINK>) assigning 1 to poorest quality and 3 to best quality: 1= trials in which concealment was inadequate (e.g. such as alternation or reference to case record numbers or to dates of birth); 2 = trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories; and 3 = trials deemed to have taken adequate measures to conceal allocation (e.g. central randomization; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque, sealed envelopes etc. that contained elements convincing of concealment).</P>
<P>Statistical methods:<BR/>We analyzed available efficacy outcomes data on intention-to-treat basis using the Cochrane Collaboration Review Manager (RevMan 4.1) software. We calculated weighted mean differences (WMD), the between-treatment difference in pooled means for outcome variables at follow-up or the pooled mean change in outcome variables between baseline and follow-up, and the 95% confidence intervals for continuous variables. A random effects model was used to allow for heterogeneity between the trials (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). Continuous variables were also evaluated by comparing differences in pooled mean scores (weighted for sample size) between baseline and follow-up measurements. We evaluated categorical events by calculating weighted relative risks and their 95% confidence intervals. The Fisher's exact test was used when cell sizes were less than 5.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-02 13:19:05 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-06-02 10:58:15 -0500" MODIFIED_BY="[Empty name]">
<P>The combined search strategies identified 46 reports of trials and 20? met our inclusion criteria.</P>
<P>LASER versus TURP (n = 18 trials)<BR/>Overall, we analyzed 19 comparisons between laser techniques and TURP because two trials each evaluated multiple laser techniques (<LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). We found eight comparisons of TURP with non-contact laser (<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Costello-1995" TYPE="STUDY">Costello 1995</LINK>; <LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gujral-2000" TYPE="STUDY">Gujral 2000</LINK>; <LINK REF="STD-Kabalin-1995" TYPE="STUDY">Kabalin 1995</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>), eight comparisons with contact laser (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Mottet-1999" TYPE="STUDY">Mottet 1999</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen-1999a" TYPE="STUDY">Tuhkanen 1999a</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>) and four comparisons with hybrid techniques (<LINK REF="STD-Carter-1999a" TYPE="STUDY">Carter 1999a</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). Two studies used holmium laser resection of the prostate (HoLRP) (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Mottet-1999" TYPE="STUDY">Mottet 1999</LINK>), the rest used neodymium yttrium-argon-garnet (Nd:YAG) lasers.</P>
<P>LASER versus Transurethral Electrovaporization (TUVP) (n = 2 trials)<BR/>We evaluated two comparisons of contact laser with transurethral electrovaporization (<LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-van-Melick-2002" TYPE="STUDY">van Melick 2002</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>).</P>
<P>LASER versus Open Prostatectomy (n = 1 trial)<BR/>We evaluated one comparison between HoLRP and open prostatectomy for treatment of prostates &gt; 100 gm (<LINK REF="STD-Kuntz-2002" TYPE="STUDY">Kuntz 2002</LINK>).</P>
<P>LASER versus Transurethral Microwave Thermotherapy (TUMT) (n = 1 trial)<BR/>We evaluated one comparison between interstitial laser coagulation and TUMT prostates &gt; 100 gm (<LINK REF="STD-Norby-2002" TYPE="STUDY">Norby 2002</LINK>).</P>
<P>We excluded studies that did not present outcomes at 6 or 12 months following treatment or that reported only economic or quality-of-life outcomes data (<LINK REF="STD-Carter-1999b" TYPE="STUDY">Carter 1999b</LINK>; <LINK REF="STD-Fraundorfer-2001" TYPE="STUDY">Fraundorfer 2001</LINK>; <LINK REF="STD-Gilling-2000" TYPE="STUDY">Gilling 2000</LINK>; <LINK REF="STD-Keoghane-1996" TYPE="STUDY">Keoghane 1996</LINK>; <LINK REF="STD-Keoghane-2000b" TYPE="STUDY">Keoghane 2000b</LINK>; <LINK REF="STD-McAllister-2000" TYPE="STUDY">McAllister 2000</LINK>; <LINK REF="STD-Shingleton-2002" TYPE="STUDY">Shingleton 2002</LINK>; <LINK REF="STD-Tuhakanen-2001" TYPE="STUDY">Tuhakanen 2001</LINK>). We also excluded studies with less than 6 months follow up (<LINK REF="STD-Langley-1997" TYPE="STUDY">Langley 1997</LINK>), those comparing different laser regimens (high vs. low power) or techniques (coagulation or evaporation) without a sham or active control (TURP) treatment arm (<LINK REF="STD-Albert-1997" TYPE="STUDY">Albert 1997</LINK>; <LINK REF="STD-Beerlage-1998" TYPE="STUDY">Beerlage 1998</LINK>; <LINK REF="STD-Boon-1995" TYPE="STUDY">Boon 1995</LINK>; <LINK REF="STD-Breteau-1997" TYPE="STUDY">Breteau 1997</LINK>; <LINK REF="STD-Bryan-1999" TYPE="STUDY">Bryan 1999</LINK>; <LINK REF="STD-de-la-Rosette-1995" TYPE="STUDY">de la Rosette 1995</LINK>; <LINK REF="STD-Narayan-1995" TYPE="STUDY">Narayan 1995</LINK>; <LINK REF="STD-Orihuela-1995" TYPE="STUDY">Orihuela 1995</LINK>), and those providing no indication of randomization or non-randomized controlled clinical trials (<LINK REF="STD-Ichiyanagi-1997" TYPE="STUDY">Ichiyanagi 1997</LINK>; <LINK REF="STD-Jung-1996" TYPE="STUDY">Jung 1996</LINK>; <LINK REF="STD-Kaplan-1995" TYPE="STUDY">Kaplan 1995</LINK>; <LINK REF="STD-Kollmorgen-1996" TYPE="STUDY">Kollmorgen 1996</LINK>; <LINK REF="STD-Matsuoka-2000" TYPE="STUDY">Matsuoka 2000</LINK>; <LINK REF="STD-Schatzl-1997" TYPE="STUDY">Schatzl 1997</LINK>; <LINK REF="STD-Wada-2000" TYPE="STUDY">Wada 2000</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-02 10:58:42 -0500" MODIFIED_BY="[Empty name]">
<P>Treatment allocation concealment was adequate in seven studies (<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Carter-1999a" TYPE="STUDY">Carter 1999a</LINK>; <LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gujral-2000" TYPE="STUDY">Gujral 2000</LINK>; <LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>) and outcomes assessors were blinded to treatment allocation in one study (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>). Nine studies reported excluding subjects in urinary retention (variably defined by a post-void residual ranging from 250 mL to 300 mL or history of being unable to void) (<LINK REF="STD-Carter-1999a" TYPE="STUDY">Carter 1999a</LINK>; <LINK REF="STD-Costello-1995" TYPE="STUDY">Costello 1995</LINK>; <LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Mottet-1999" TYPE="STUDY">Mottet 1999</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>; <LINK REF="STD-Tuhkanen-1999a" TYPE="STUDY">Tuhkanen 1999a</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>). Ten studies provided 12 or more months of follow up. The overall proportion of subjects available for follow-up ranged from 53% to 97% in studies with at 12 months of follow up and 89% to 99% in studies with less than 12 months of follow up.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-02 13:19:05 -0500" MODIFIED_BY="[Empty name]">
<P>LASER vs. Transurethral Resection of the Prostate (TURP)<BR/>A total of 1488 participants were randomized in the 16 trials, including 733 to TURP, 374 to non-contact laser techniques, 244 to contact laser techniques, and 137 to hybrid laser techniques. The mean age, (67.4 years, range 61 to 70.6 years), mean baseline symptom score (20.2, range 15.7 to 24.7), and the mean baseline peak urinary flow (9.5 mL/s, range 6.2 to 12.2 mL/s) did not differ by treatment group.</P>
<P>Operative time, hospital length-of-stay, catheter duration, and treatment failure data are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>, and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>. Non-contact laser procedures consistently took less time than TURP, ranging from 13 to 43 minutes compared to 20 to 58 minutes (<LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Kabalin-1995" TYPE="STUDY">Kabalin 1995</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>). Contact and hybrid procedures took similar or longer amounts of time than TURP, ranging from 19 to 88 minutes compared to 20 to 106 minutes for TURP. Hospital length of stay, reported by 10 studies, was significantly less following laser treatment, with differences ranging from 1 to 2 days. No study reported a shorter hospital length of stay with TURP. Duration of urinary catheter placement was significantly shorter following TURP in three non-contact studies [<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gujral-2000" TYPE="STUDY">Gujral 2000</LINK>], one contact study [<LINK REF="STD-Tuhkanen-1999a" TYPE="STUDY">Tuhkanen 1999a</LINK>], and one hybrid study (<LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>), with differences ranging from 10 hours to 22.5 days. The duration of urinary catheter placement was significantly shorter following laser techniques in one non-contact study (<LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>), four contact studies (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>), and one hybrid study (<LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). Treatment failure leading to re-operation was more likely following laser techniques (28/528) than TURP (5/537), relative risk (RR) = 5.7, 95% CI, 2.2 to 14.6.</P>
<P>Outcomes:<BR/>All studies found significant decreases in urinary symptoms and significant increases in peak urinary flow between baseline and follow-up for both TURP and laser techniques (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
<P>Non-contact lasers versus TURP<BR/>Non-contact lasers provided similar improvement in LUTS in comparison to TURP. The pooled mean symptom score for men undergoing non-contact laser techniques decreased 59% by 12 months (19 to 7.7) versus 63% (19.3 to 7.1) in the men undergoing TURP. Weighted mean differences between treatments varied depending upon whether studies reported mean changes or mean values at follow up. The WMD for 3 studies reporting mean changes in urinary symptom scores was - 2.47 points (95% CI, -4.24 to -0.70) significantly favoring TURP (<LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gujral-2000" TYPE="STUDY">Gujral 2000</LINK>) (figure 01.01). For the 4 studies reporting only the mean urinary symptom scores at follow-up, and the WMD was 0.21 (95% CI, -2.28, 2.70) favoring laser [<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Kabalin-1995" TYPE="STUDY">Kabalin 1995</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>] (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).<BR/>
<BR/>TURP led to greater improvement in urinary flow in three comparisons with non-contact laser, ranging from 1.6 mL to 6.4 mL/s higher at follow up (<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>). The pooled mean peak urinary flow for men undergoing non-contact laser techniques increased 56% (10.1 to 15.8 mL/s) versus 96% (9.8 mL to 19.2 mL/s) in men undergoing TURP. Three studies reported mean changes in peak urinary flow, the WMD was 3.18 mL/s (95% CI, 1.47 to 4.89) significantly favoring TURP (<LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Gujral-2000" TYPE="STUDY">Gujral 2000</LINK>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Four other studies reported mean peak urinary flow data at follow-up, the WMD was 2.64 (95% CI, 0.53 to 4.75) favoring TURP (<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Kabalin-1995" TYPE="STUDY">Kabalin 1995</LINK>; <LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Contact lasers versus TURP<BR/>We evaluated Nd:YAG and HoLRP separately because of their different tissue effects; NdYAG lasers vaporize tissue while HoLRP lasers vaporize and excise tissue. In three comparisons with Nd:YAG lasers, TURP led to greater improvement in symptoms, ranging from 2.9 to 4.0 points lower at follow up (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). The pooled mean symptom score for men undergoing Nd:YAG contact laser treatments decreased 66% by 12 months (22.4 to 7.7) versus 78% (20.5 to 4.5) for men undergoing TURP (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). Three Nd:YAG studies reported mean urinary symptom scores at follow-up, the weighted mean difference for Nd:YAG contact lasers versus TURP was -2.08 points (95% CI, -4.51 to 0.36) favoring TURP (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). There were no differences in symptom scores between men treated with HoLRP versus TURP. The pooled mean symptom score for men undergoing HoLRP laser treatments decreased by 79% (21.4 to 4.5) versus 81% (23.1 to 4.4) for men undergoing TURP (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Mottet-1999" TYPE="STUDY">Mottet 1999</LINK>). The weighted mean difference for HoLRP versus TURP was 0.10 points (95% CI, -1.88 to 2.08), favoring laser (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>None of the Nd:YAG laser studies found statistically significant differences between treatments in improving peak urinary flow. The pooled mean peak urinary flow for men undergoing Nd:YAG laser treatments increased by 85% (10.0 mL/s to 18.5 mL/s) versus 125% (9.6 mL/s to 21.6 mL/s) in men undergoing TURP (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). Five Nd:YAG studies reported peak urinary flow at follow up, the weighted mean difference for lasers versus TURP was 1.72 mL/s (95% CI, -0.32 to 3.76) favoring TURP (<LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). For men undergoing Ho:YAG treatment, peak urinary flow increased by 175% (8.8 mL/s to 24.2 mL/s) versus 128% (8.8 mL/s to 20.1 mL/s) in men undergoing TURP (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>; <LINK REF="STD-Mottet-1999" TYPE="STUDY">Mottet 1999</LINK>). One HoLRP study reported peak urinary flow at follow up and the weighted mean difference favored HoLRP (-4.80 mL/s, 95% CI -8.79 to -0.81) (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Hybrid lasers versus TURP<BR/>The pooled mean symptom score for men undergoing hybrid laser techniques decreased 67% by 12 months (20.5 to 6.8) versus 71% (20.3 to 5.8) in men undergoing TURP. TURP led to significantly better improvement in symptoms than hybrid laser techniques in one study (<LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). No studies provided data on mean urinary symptom scores at follow up.</P>
<P>The pooled mean peak urinary flow for men undergoing hybrid laser techniques increased 109% by 12 months (9.3 mL/s to 19.1 mL/s) versus 107% (9.9 mL/s to 20.5 mL/s) in men undergoing TURP. Three studies reported mean peak urinary flow at follow up, the weighted mean difference for hybrid lasers versus TURP was 1.53 (95% CI, -1.13 to 4.19) favoring TURP (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (<LINK REF="STD-Carter-1999a" TYPE="STUDY">Carter 1999a</LINK>; <LINK REF="STD-Suvakovic-1996" TYPE="STUDY">Suvakovic 1996</LINK>; <LINK REF="STD-Tuhkanen--1999b" TYPE="STUDY">Tuhkanen 1999b</LINK>).</P>
<P>Adverse events (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>):<BR/>Most trials did not comprehensively report adverse events. The frequencies of adverse events associated with TURP and laser techniques are shown in Table 4. Overall, subjects undergoing laser techniques had less morbidity and fewer complications. More men undergoing TURP required transfusions (6.7%, 49/735 subjects vs. &lt; 1% 2/720; RR = 24, 95% CI 5.9 to 98) and developed strictures (8.2%, 43/527 vs. 3.8%, 20/520; RR = 2.1, 95% CI 1.3 to 3.6) than men receiving any laser procedure.</P>
<P>We found no differences between TURP and laser groups in erectile dysfunction, retrograde ejaculation, TURP syndrome, epididymitis/orchitis, clot retention, or urinary incontinence. However, urinary retention was more common following laser techniques (RR = 2.4, 95% CI 1.5 to 3.9) and non-contact laser techniques caused more dysuria than TURP (RR = 3.6, 95% CI, 1.0 to 13.1). No treatment-related deaths were reported, though one patient died of a myocardial infarction eight days after uncomplicated HoLRP (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>).</P>
<P>CONTACT LASER versus Transurethral Electrovaporization (TUVP) (n = 2 trials)<BR/>A total of 122 subjects were randomized in two trials of Nd:Yag contact lasers (n = 56) versus transurethral electrovaporization (TUVP) (n = 66) (<LINK REF="STD-Shingleton-1998" TYPE="STUDY">Shingleton 1998</LINK>; <LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>). Van Melick and colleagues reported similar operative times for the two procedures, 58 minutes for contact laser compared with 50 minutes for electrovaporization, and similar hospital length of stay, 3.8 versus 3.4 days, respectively (<LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>). Neither study reported on catheter duration; Van Melick and colleagues reported one (2%) reoperation during six months follow up after contact laser and 2 (4%) reoperations following electrovaporization.</P>
<P>Both treatments were equally effective for relieving BPO symptoms and improving urinary flow. The contact lasers reduced pooled mean symptom scores by 67% (18.9 to 6.3) at 6-month follow up while the TUEV reduced symptom scores by 68% (20.8 to 6.6). Pooled mean peak urinary flow increased 106% (10.9 mL/s to 22.5 mL/s) following contact laser and 104% (10.0 to 20.4 mL/s) following TUVP.</P>
<P>Urinary retention developed following 8 (14.3%) contact laser procedures and 1 (1.5%) TUVP procedure. Shingleton and colleagues reported 1 stricture following contact laser and one following TUVP; new erectile dysfunction was reported in 9% and 10% of laser and TUVP subjects, respectively, who had normal function at baseline (<LINK REF="STD-Shingleton-1998" TYPE="STUDY">Shingleton 1998</LINK>). Van Melick and colleagues reported 2 (4.3%) cases of clot retention following TUVP; no clot retention developed following contact laser and neither group required transfusions (<LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>). A similar proportion (8% vs. 10%) of subjects developed urinary tract infections following contact laser and TUVP, respectively (<LINK REF="STD-van-Melick-2003" TYPE="STUDY">van Melick 2003</LINK>).</P>
<P>INTERSTITIAL LASER COAGULATION versus Transurethral Microwave Thermotherapy (TUMT ) (n = 1 trial)<BR/>Norby and colleagues (<LINK REF="STD-Norby-2002" TYPE="STUDY">Norby 2002</LINK>) compared interstitial laser coagulation (n = 48) with transurethral thermotherapy (n = 46). TUMT was performed as an outpatient procedure, the median length of stay for ILC was three days. Median catheter duration was 3 days following ILC, and 7 to 14 days following TUMT, with longer catheterization required after higher energy procedures. During six months of follow up, one TUMT patient underwent reoperation for BPO compared to none in the ILC group.</P>
<P>Both treatments were equally effective for relieving BPO symptoms and improving urinary flow. The ILC reduced mean symptom scores by 56% (21.4 to 9.5) at 6-month follow-up while the TUMT reduced mean symptom scores by 54% (20.5 to 9.5). Mean peak urinary flow increased 59% (10.2 mL/s to 16.2 mL/s) following ILC and 45% (9.1 mL/s to 13.2 mL/s) following TURP.</P>
<P>Subjects undergoing ILC were twice as likely (61% vs. 30%) to develop a urinary tract infection. Urinary retention occurred in 4 (9%) subjects following ILC and 3 (7%) subjects following TUMT. One ILC subject developed a stricture, none had clot retention or urinary incontinence. One TUMT subject had clot retention, none developed a stricture or urinary incontinence. Among men with normal sexual function, 29% developed erectile dysfunction and 35% developed retrograde ejaculation following ILC. The corresponding proportions were 9% and 22%, respectively, following TUMT.</P>
<P>CONTACT LASER versus Open Prostatectomy (n = 1 trial)<BR/>One study (<LINK REF="STD-Kuntz-2002" TYPE="STUDY">Kuntz 2002</LINK>) compared HoLRP (n = 60) with open prostatectomy (n = 60) to treat men with large prostates (&gt; 100 gm) with PVR &gt; 50 mL. Operative time was significantly longer with HoLRP (136 vs. 91 minutes, P &lt; 0.0001), while hospital length of stay was significantly longer with open prostatectomy (251 vs. 70 hours, P &lt; 0.0001) as was catheter duration (194 vs. 31 hours, P &lt; 0.0001). During follow up, six laser subjects underwent reoperation, two for BPO, three for bleeding, and one for stricture. Following open prostatectomy, reoperation was required by three subjects for bleeding and by two subjects for strictures.</P>
<P>Both treatments were equally effective for BPO resulting from large prostates. The HoLRP reduced mean symptom scores by 89% (22.1 to 2.4) at 6-month follow up while the open prostatectomy reduced mean symptom scores by 87% (21.1 to 2.8). Mean peak urinary flow increased from 3.8 mL/s to 29.9 mL/s following HoLRP and 3.6 mL/s to 27.0 mL/s following open prostatectomy. The baseline PUF values for this study were markedly low.</P>
<P>Eight (13%) subjects required transfusion following open prostatectomy compared to none of the HoLRP subjects. Six (10%) subjects developed urinary incontinence following open prostatectomy compared to five (8%) of the HoLRP subjects. Erectile dysfunction developed in 10% of open prostatectomy and 9% of HoLRP subjects with normal baseline erectile function; 79% of open prostatectomy subjects developed retrograde ejaculation compared to 70% of HoLRP subjects. Neither difference was statistically significant.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-06-02 13:20:04 -0500" MODIFIED_BY="[Empty name]">
<P>Our systematic review found that laser techniques were effective in reducing lower urinary tract symptoms attributable to BPO and in improving peak urinary flow for up to one year following surgery. Symptom scores were reduced by about 70% and urinary flow usually doubled. Urinary symptom and flow outcomes following laser surgery were generally similar to TURP, though a number of studies found significantly better results following TURP (<LINK REF="STD-Anson-1995" TYPE="STUDY">Anson 1995</LINK>; <LINK REF="STD-Cowles-1995" TYPE="STUDY">Cowles 1995</LINK>; <LINK REF="STD-Donovan-2000" TYPE="STUDY">Donovan 2000</LINK>; <LINK REF="STD-Keoghane-2000a" TYPE="STUDY">Keoghane 2000a</LINK>; <LINK REF="STD-Shingleton-1999" TYPE="STUDY">Shingleton 1999</LINK>; <LINK REF="STD-Zorn-1999" TYPE="STUDY">Zorn 1999</LINK>). Only one study found a laser technique (non-contact) more effective than TURP in improving urinary symptoms [<LINK REF="STD-Sengor-1996" TYPE="STUDY">Sengor 1996</LINK>] and only one study found a laser technique (HoLRP) more effective in improving peak urinary flow (<LINK REF="STD-Gilling-1999" TYPE="STUDY">Gilling 1999</LINK>). Hospital lengths of stay were shorter with laser techniques compared to TURP. The operating time for TURP was about the same or shorter than for contact procedures, but TURP took longer than non-contact procedures. Contact laser procedures had the shortest duration of urinary catheter placement followed by TURP and then non-contact laser procedures. Adverse events generally occurred less frequently with laser techniques, particularly transfusion, clot retention, strictures, and TUR syndrome. The occurrence of urinary tract infections was similar between laser techniques and TURP, but non-contact procedures led to a substantially higher occurrence of dysuria than either TURP or contact laser procedures. The re-operation rate was higher during the 12 months following laser techniques than with TURP.</P>
<P>Baseline characteristics, including age, symptoms, and flow measures, were similar to subjects enrolled in other surgical studies of BPO treatment suggesting that our results are generalizable. The average age of study subjects was 67 years and baseline symptom and urinary flow measures were consistent with moderately severe obstruction. However, men with extremely large prostates or acute retention were generally excluded.</P>
<P>Although we limited our analysis to randomized controlled trials, the majority of the studies had potential methodologic flaws. Just seven studies clearly had adequate concealment of randomization and only one study blinded study personnel. Studies did not consistently report comprehensive information on efficacy outcomes and adverse events, particularly dysuria and erectile dysfunction, and our estimates for these events may be unreliable. Only three studies, which used non-contact techniques, reported data on the mean changes in urinary symptom scores and peak urinary flow; just 11 studies reported mean values for these outcomes at follow up. Consequently, we were often unable to pool data, limiting our ability to statistically assess the relative efficacy of laser techniques versus TURP, open prostatectomy, and other kinds of minimally invasive techniques. Several studies provided follow up beyond one year, but outcome data were unreliable because sample sizes were small and the rates of attrition were high (<LINK REF="STD-Keoghane-1996" TYPE="STUDY">Keoghane 1996</LINK>; <LINK REF="STD-Gilling-2000" TYPE="STUDY">Gilling 2000</LINK>; <LINK REF="STD-McAllister-2000" TYPE="STUDY">McAllister 2000</LINK>; <LINK REF="STD-Shingleton-2002" TYPE="STUDY">Shingleton 2002</LINK>; <LINK REF="STD-Tuhakanen-2001" TYPE="STUDY">Tuhakanen 2001</LINK>). There were too few studies to determine whether variations in laser energy source, power setting, laser wavelength, or treatment duration and location affected outcomes. Similarly, there were too few studies to adequately compare laser techniques with other minimally invasive procedures such as TUMT or TUVP.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Patients and providers can use the information provided by this systematic review to weigh the relative risks and benefits of TURP and laser procedures. Improvements in urinary symptoms and flow slightly favored TURP, though laser procedures had fewer adverse events and shorter hospitalizations. The risk of re-operation was higher following laser procedures. Data were insufficient to adequately compare laser techniques with other minimally invasive procedures. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Despite the widespread use of laser procedures, relatively few subjects have been studied in controlled clinical trials. Further studies, using randomized treatment allocation, larger sample sizes, and comprehensive measures of outcomes and adverse events, are still needed to better define the role of laser techniques for treating BPO.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to acknowledge Indulis Rutks for his work on literature search and article retrieval and Dr. Claudia Cucino for help with translations. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>R Hoffman made contributions to acquisition, analysis and interpretation of data, and drafting of manuscript. R MacDonald made contributions to analysis and interpretation of data, statistical expertise, and administrative, technical and material support. T Wilt contribituted to conception and design of the study, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, statistical expertise, obtaining funding, and overall supervision.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-02 10:37:38 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-06-02 10:37:17 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Anson-1995" NAME="Anson 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anson K, Nawrocki J, Buckley J, Fowler C, Kirby R, Lawrence W, Paterson P, Watson, G</AU>
<TI>A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate</TI>
<SO>Urology</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>3</NO>
<PG>305-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95389563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckley JF, Ligam V, Paterson P and the British ELAP Group</AU>
<TO>Endoscopic laser ablation of the prostate gland (ELAP)</TO>
<SO>J Urol</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>Abstract 5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1999a" NAME="Carter 1999a" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carter A, Sells H, Speakman M, Ewings P, MacDonagh R, O'Boyle P</AU>
<TI>A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up</TI>
<SO>BJU Int</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>3</NO>
<PG>254-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99252378 99252378"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costello-1995" NAME="Costello 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costello AJ, Crowe HR, Jackson T, Street A</AU>
<TI>A randomised single institution study comparing laser prostatectomy and transurethral resection of the prostate</TI>
<SO>Ann Acad Med Sing</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>5</NO>
<PG>700-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96161385"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowles-1995" NAME="Cowles 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowles RS 3rd, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A</AU>
<TI>A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia</TI>
<SO>Urology</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95350893"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donovan-2000" NAME="Donovan 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN, Wright M, Kennedy LG, Abrams P</AU>
<TI>A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study</TI>
<SO>J Urol</SO>
<YR>2000</YR>
<VL>164</VL>
<NO>1</NO>
<PG>65-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20300803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilling-1998a" NAME="Gilling 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilling PJ. Cass CB. Malcolm A. Cresswell M. Fraundorfer MR. Kabalin JN</AU>
<TI>Holmium laser resection of the prostate versus neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate: a randomized prospective comparison of two techniques for laser prostatectomy</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>4</NO>
<PG>573-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98246021"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilling-1999" NAME="Gilling 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR</AU>
<TI>Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup</TI>
<SO>J Urol</SO>
<YR>1999</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1640-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99452518"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gujral-2000" NAME="Gujral 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gujral S, Abrams P, Donovan JL, Neal DE, Brookes ST, Chacko KN, Wright MJP, Timoney AG, Peters TJ</AU>
<TI>A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention</TI>
<SO>J Urol</SO>
<YR>2000</YR>
<VL>164</VL>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabalin-1995" NAME="Kabalin 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabalin JN, Gill HS, Bite G, Wolfe V</AU>
<TI>Comparative study of laser versus electrocautery prostatic resection: 18-month followup with complex urodynamic assessment</TI>
<SO>J Urol</SO>
<YR>1995</YR>
<VL>153</VL>
<NO>1</NO>
<PG>94-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95056260"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kabalin JN</AU>
<TI>Laser prostatectomy performed with a right angle firing neodymium:YAG laser fiber at 40 watts power setting</TI>
<SO>J Urol</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>1</NO>
<PG>95-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keoghane-2000a" NAME="Keoghane 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keoghane SR, Cranston DW, Lawrence KC, Doll HA, Fellows GJ, Smith JC</AU>
<TI>The Oxford Laser Prostate Trial: a double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results</TI>
<SO>Br J Urol</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>382-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96247131 96247131"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keoghane SR, Lawrence KC, Jenkinson CP, Doll HA, Chappel DB, Cranston DW</AU>
<TI>The Oxford Laser Prostate Trial: sensitivity to change of three measures of outcome</TI>
<SO>Urology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96149735"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keoghane SR. Doll HA. Lawrence KC. Jenkinson CP. Cranston DW</AU>
<TI>The Oxford Laser Prostate Trial: sexual function data from a randomized controlled clinical trial of contact laser prostatectomy</TI>
<SO>Eur Urol</SO>
<YR>1996</YR>
<VL>30</VL>
<NO>4</NO>
<PG>424-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97131410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuntz-2002" NAME="Kuntz 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;J Urol. 2002 Oct;168(4 Pt 1):1465-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuntz RM, Lehrich K</AU>
<TI>Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm: a randomized prospective trial of 120 patients</TI>
<SO>J Urol</SO>
<YR>2002</YR>
<VL>168</VL>
<NO>4 Pt 1</NO>
<PG>1465-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mottet-1999" NAME="Mottet 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mottet N, Anidjar M, Bourdon O, Louis JF, Teillac P, Costa P, Le Duc A</AU>
<TI>Randomized comparison of transurethral electroresection and holmium: YAG laser vaporization for symptomatic benign prostatic hyperplasia</TI>
<SO>J Endourol</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>127-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99228096"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norby-2002" NAME="Norby 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;BJU Int. 2002 Dec;90(9):853-62&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norby B, Nielsen HV, Frimodt-Moller PC</AU>
<TI>Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia</TI>
<SO>BJU Int</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>9</NO>
<PG>853-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sengor-1996" NAME="Sengor 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;[published erratum appears in Br J Urol 1997 Feb;79(2):304]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sengor F, Kose O, Yucebas E, Beysel M, Erdogan K, Narter F</AU>
<TI>A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-month follow-up</TI>
<SO>Br J Urol</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>3</NO>
<PG>398-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97036301 97036301"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shingleton-1998" NAME="Shingleton 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Shingleton WB, Renfroe LD, Kolski JM, Fowler JE, Jr. A randomized prospective study of transurethral electrovaporization vs laser ablation of the prostate in men with benign prostatic hypertrophy. Scand J Urol Nephrol 1998;32:266-9&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shingleton WB, Renfroe LD, Kolski JM, Fowler JE, Jr</AU>
<TI>A randomized prospective study of transurethral electrovaporization vs laser ablation of the prostate in men with benign prostatic hypertrophy</TI>
<SO>Scand J Urol Nephrol</SO>
<YR>1998</YR>
<VL>32</VL>
<PG>266-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shingleton-1999" NAME="Shingleton 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shingleton WB, Terrell F, Renfroe DL, Kolski JM, Fowler JE Jr</AU>
<TI>A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia</TI>
<SO>Urology</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>6</NO>
<PG>1017-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20068201"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suvakovic-1996" NAME="Suvakovic 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Suvakovic N, Hindmarsh JR. A step towards day case prostatectomy. Br J Urol 1996;77:212-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suvakovic N, Hindmarsh JR</AU>
<TI>A step towards day case prostatectomy.</TI>
<SO>Br J Urol</SO>
<YR>1996</YR>
<VL>77</VL>
<PG>212-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuhkanen--1999b" NAME="Tuhkanen  1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuhkanen K, Heino A, Alaopas M</AU>
<TI>Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up</TI>
<SO>BJU Int</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>7</NO>
<PG>805-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20004685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuhkanen-1999a" NAME="Tuhkanen 1999a" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Tuhkanen K, Heino A, Ala-Opas M. Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment. Scand J Urol Nephrol 1999;33:31-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuhkanen K, Heino A, Ala-Opas M</AU>
<TI>Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment</TI>
<SO>Scand J Urol Nephrol</SO>
<YR>1999</YR>
<VL>33</VL>
<PG>31-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Melick-2002" NAME="van Melick 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;J Urol. 2002 Sep;168(3):1058-62&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA</AU>
<TI>A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects</TI>
<SO>J Urol</SO>
<YR>2002</YR>
<VL>168</VL>
<NO>3</NO>
<PG>1058-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Melick-2003" NAME="van Melick 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;J Urol. 2003 Apr;169(4):1411-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Melick HH, van Venrooij GE, Eckhardt MD, Boon TA</AU>
<TI>A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality</TI>
<SO>J Urol</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>4</NO>
<PG>1411-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zorn-1999" NAME="Zorn 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zorn BH, Bauer JJ, Ruiz HE, Thrasher JB</AU>
<TI>Randomized trial of safety and efficacy of transurethral resection of the prostate using contact laser versus electrocautery</TI>
<SO>Techniques in Urology</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>198-201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20057215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-1997" NAME="Albert 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert P, Bretheau D, Taverna GL, Aimino R, Morin N, Salvo A</AU>
<TO>Laser-assisted endoscopic resection: a new surgical technique for the treatment of benign prostatic hypertrophy. Preliminary results of a study involving 100 patients [Italian]</TO>
<SO>Arch Ital Urol Androl</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beerlage-1998" NAME="Beerlage 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Beerlage HP, Francisca EA, d'Ancona FC, Debruyne FM, De la Rosette JJ. Urolase v ultraline fibers in laser prostatectomy: 3-year follow-up of a randomized study. J Endourol 1998;12:575-80&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beerlage HP, Francisca EA, d'Ancona FC, Debruyne FM, De la Rosette JJ</AU>
<TO>Urolase v ultraline fibers in laser prostatectomy: 3-year follow-up of a randomized study</TO>
<SO>J Endourol</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boon-1995" NAME="Boon 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boon TA, van Swol CF, van Venrooij GE, Beerlage HP, Verdaasdonk RM</AU>
<TO>Laser prostatectomy for patients with benign prostatic hyperplasia: a prospective randomized study comparing two different techniques using the Prolase-II fiber</TO>
<SO>World J Urol</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>123-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95353309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breteau-1997" NAME="Breteau 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breteau D, Koutani A, Albert P, Morin N, Salvo A</AU>
<TI>The VLAP system (Visual Laser Ablation of the Prostate): comparative study of the contact versus non-contact techniques in a series of 100 cases [French]</TI>
<SO>Prog Urol CONFIRM</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>2</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryan-1999" NAME="Bryan 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryan NP, Byrne L, Hastie KJ, Anderson JB, Moore KT, Chapple CR</AU>
<TO>A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate</TO>
<SO>BJU Int</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99252377"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1999b" NAME="Carter 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter A, Sells H, Speakman M, Ewings P, O'Boyle P, MacDonagh R</AU>
<TO>Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP</TO>
<SO>Eur Urol</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>92-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-la-Rosette-1995" NAME="de la Rosette 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beerlage HP, Francisca EA, d'Ancona FC, Debruyne FM, De la Rosette JJ</AU>
<TO>Urolase v ultraline fibers in laser prostatectomy: 3-year follow-up of a randomized study</TO>
<SO>J Endourol</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>6</NO>
<PG>575-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99110582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de la Rosette JJ, te Slaa E, de Wildt MJ, Debruyne FM</AU>
<TO>Experience with the Ultraline and Urolase laser fibers: is there any difference?</TO>
<SO>World J Urol</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>98-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9535331995353319"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fraundorfer-2001" NAME="Fraundorfer 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG. Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study. Urology 2001;57:454-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG</AU>
<TO>Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study</TO>
<SO>Urology</SO>
<YR>2001</YR>
<VL>57</VL>
<PG>454-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilling-1998b" NAME="Gilling 1998b" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Gilling PJ, Cass CB, Malcolm A, Cresswell M, Fraundorfer MR, Kabalin JN. Holmium laser resection of the prostate versus neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate: a randomized prospective comparison of two techniques for laser prostatectomy. Urology 1998;51:573-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilling PJ, Cass CB, Malcolm A, Cresswell M, Fraundorfer MR, Kabalin JN</AU>
<TO>Holmium laser resection of the prostate versus neodymium:yttrium-aluminum-garnet visual laser ablation of the prostate: a randomized prospective comparison of two techniques for laser prostatectomy</TO>
<SO>Urology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>573-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilling-2000" NAME="Gilling 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up. J Endourol 2000;14:757-60&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilling PJ, Kennett KM, Fraundorfer MR</AU>
<TO>Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up</TO>
<SO>J Endourol</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>757-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ichiyanagi-1997" NAME="Ichiyanagi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichiyanagi O, Ishigooka M, Hashimoto T, Hayani S, Suzuki Y, Nakada T</AU>
<TO>The American Urological Association Symptom Index: early postoperative evaluation of irritative and obstructive symptoms due to benign prostatic hyperplasia</TO>
<SO>Int Urol Nephrol</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>4</NO>
<PG>441-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98069076"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-1996" NAME="Jung 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung P, Mattelaer P, Wolff JM, Mersdorf A, Jakse G</AU>
<TO>Visual laser ablation of the prostate: efficacy evaluated by urodynamics and compared to TURP</TO>
<SO>Eur Urol</SO>
<YR>1996</YR>
<VL>30</VL>
<NO>4</NO>
<PG>418-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97131409"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1995" NAME="Kaplan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Kaplan SA, Te AE. A comparative study of transurethral resection of the prostate using a modified electro-vaporizing loop and transurethral laser vaporization of the prostate. J Urol 1995;154:1785-90&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan SA, Te AE</AU>
<TO>A comparative study of transurethral resection of the prostate using a modified electro-vaporizing loop and transurethral laser vaporization of the prostate</TO>
<SO>J Urol</SO>
<YR>1995</YR>
<VL>154</VL>
<PG>1785-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keoghane-1996" NAME="Keoghane 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Keoghane SR, Lawrence KC, Gray AM, Chappel DB, Hancock AM, Cranston DW. The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy. Br J Urol 1996;77:386-90&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keoghane SR, Lawrence KC, Gray AM, Chappel DB, Hancock AM, Cranston DW</AU>
<TO>The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy</TO>
<SO>Br J Urol</SO>
<YR>1996</YR>
<VL>77</VL>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keoghane-2000b" NAME="Keoghane 2000b" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keoghane SR, Lawrence KC, Gray AM, Doll HA, Hancock AM, Turner K, Sullivan ME, Dyar O, Cranston D</AU>
<TO>A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up</TO>
<SO>BJU Int</SO>
<YR>2000</YR>
<VL>85</VL>
<PG>74-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kollmorgen-1996" NAME="Kollmorgen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kollmorgen TA, Malek RS, Barrett DM</AU>
<TO>Laser prostatectomy: two and a half years' experience with aggressive multifocal therapy</TO>
<SO>Urology</SO>
<YR>1996</YR>
<VL>48</VL>
<NO>2</NO>
<PG>217-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96352713"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langley-1997" NAME="Langley 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langley SE, Gallegos CR, Moisey CU</AU>
<TO>A prospective randomized trial evaluating endoscopic Nd:YAG laser prostate ablation with or without potassium titanyl phosphate (KTP) laser bladder neck incision</TO>
<SO>Br J Urol</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>6</NO>
<PG>880-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9810251198102511"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuoka-2000" NAME="Matsuoka 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Matsuoka K, Iida S, Tomiyasu K, Shimada A, Noda S. Transurethral holmium laser resection of the prostate. J Urol 2000;163:515-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuoka K, Iida S, Tomiyasu K, Shimada A, Noda S</AU>
<TO>Transurethral holmium laser resection of the prostate</TO>
<SO>J Urol</SO>
<YR>2000</YR>
<VL>163</VL>
<PG>515-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAllister-2000" NAME="McAllister 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAllister WJ, Absalom MJ, Mir K, Shivde S, Anson K, Kirby RS, Lawrence WT, Paterson PJ, Watson GM, Fowler CG.</AU>
<TO>Does endoscopic laser ablation of the prostate stand the test of time? Five-year results from a multicentre randomized controlled trial of endoscopic laser ablation against transurethral resection of the prostate.</TO>
<SO>BJU Int</SO>
<YR>2000</YR>
<VL>85</VL>
<PG>437-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muschter-1995" NAME="Muschter 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muschter R, Hofstetter A</AU>
<TO>Interstitial laser therapy outcomes in benign prostatic hyperplasia</TO>
<SO>J Endourol</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>2</NO>
<PG>129-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9536003695360036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narayan-1995" NAME="Narayan 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narayan P, Tewari A, Aboseif S, Evans C</AU>
<TO>A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia</TO>
<SO>J Urol</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>6</NO>
<PG>2083-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orihuela-1995" NAME="Orihuela 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orihuela E, Motamedi M, Pow-Sang M, DeAngelis A, Cammack T, LaHaye M, Torres J, Warren MM</AU>
<TO>Randomized clinical trial comparing low power-slow heating versus high power-rapid heating noncontact neodymium:yttrium-aluminum-garnet laser regimens for the treatment of benign prostatic hyperplasia</TO>
<SO>Urology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>5</NO>
<PG>783-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schatzl-1997" NAME="Schatzl 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol 2000;37:695-701&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M</AU>
<TO>Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options</TO>
<SO>Eur Urol</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>695-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schatzl G, Madersbacher S, Lang T, Marberger M</AU>
<TO>The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives</TO>
<SO>J Urol</SO>
<YR>1997</YR>
<VL>158</VL>
<NO>1</NO>
<PG>105-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9732987597329875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shingleton-2002" NAME="Shingleton 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Urology. 2002 Aug;60(2):305-8.  Related Articles, Links  &lt;/p&gt;&lt;p&gt;&lt;br&gt;Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia.&lt;/p&gt;&lt;p&gt;Shingleton WB, Farabaugh P, May W.&lt;/p&gt;&lt;p&gt;Urology. 2002 Aug;60(2):305-8.  Related Articles, Links  &lt;/p&gt;&lt;p&gt;&lt;br&gt;Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia.&lt;/p&gt;&lt;p&gt;Shingleton WB, Farabaugh P, May W.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shingleton WB, Farabaugh P, May W</AU>
<TI>Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia</TI>
<SO>Urology</SO>
<YR>2002</YR>
<VL>60</VL>
<NO>2</NO>
<PG>305-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuhakanen-2001" NAME="Tuhakanen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuhkanen K, Heino A, Ala-Opas M</AU>
<TO>Two-year follow-up results of a prospective randomized trial comparing hybrid laser prostatectomy with TURP in the treatment of big benign prostates</TO>
<SO>Scand J Urol Nephrol</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>200-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wada-2000" NAME="Wada 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Wada S, Yoshimura R, Kyo M, Hase T, Masuda C, Watanabe Y, et al. Comparative study of transurethral laser prostatectomy versus transurethral electroresection for benign prostatic hyperplasia. Int J Urol 2000;7:373-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wada S, Yoshimura R, Kyo M, Hase T, Masuda C, Watanabe Y, et al</AU>
<TO>Comparative study of transurethral laser prostatectomy versus transurethral electroresection for benign prostatic hyperplasia</TO>
<SO>Int J Urol</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>373-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-06-02 10:37:17 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Beisland-1989" NAME="Beisland 1989" YEAR="1989">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCullough-1994" MODIFIED="2008-06-02 10:37:17 -0500" MODIFIED_BY="[Empty name]" NAME="McCullough 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCullough DL</AU>
<TO>Transurethral ultrasound-guided laser induced prostatectomy (TULIP) for the treatment of BPH</TO>
<SO>Seminars in Urology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>3</NO>
<PG>161-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95090287"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-02 10:37:38 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Albert-1997" NAME="Albert 1997" NOTES="&lt;p&gt;Albert P, Bretheau D, Taverna GL, Aimino R, Morin N, Salvo A. [Laser-assisted endoscopic resection: a new surgical technique for the treatment of benign prostatic hypertrophy. Preliminary results of a study involving 100 patients]. [Italian]. Arch Ital Urol Androl 1997;69:15-21&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Albert P, Bretheau D, Taverna GL, Aimino R, Morin N, Salvo A</AU>
<TI>Laser-assisted endoscopic resection: a new surgical technique for the treatment of benign prostatic hypertrophy. Preliminary results of a study involving 100 patients [Italian]</TI>
<SO>Arch Ital Urol Androl</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AUA-2003" NAME="AUA 2003" TYPE="JOURNAL_ARTICLE">
<AU>AUA Practice Guidelines Committee</AU>
<TI>AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations</TI>
<SO>J Urol</SO>
<YR>2003</YR>
<VL>170(2 Pt 1)</VL>
<PG>530-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barry-1990" NAME="Barry 1990" NOTES="&lt;p&gt;Barry MJ. Medical outcomes research and benign prostatic hyperplasia. Prostate 1990;3 (Suppl):61-74&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Barry MJ</AU>
<TI>Medical outcomes research and benign prostatic hyperplasia</TI>
<SO>Prostate</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>Suppl</NO>
<PG>61-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Control Clin Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Indentifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>312</VL>
<PG>944-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dixon-1995" NAME="Dixon 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dixon CM</AU>
<TI>Lasers for treatment of benign prostatic hyperplasia</TI>
<SO>Urol Clin North Am</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jepsen-1998" NAME="Jepsen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jepsen JV, Bruskewitz RC</AU>
<TI>Recent developments in the surgical management of benign prostatic hyperplasia</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>Suppl 4A</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1998" NAME="Kaplan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan SA</AU>
<TI>Minimally invasive alternative therapeutic options for lower urinary tract symptoms</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>Suppl 4A</NO>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lepor-1996" NAME="Lepor 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lepor H, Oesterling JE, Wasson JH</AU>
<TI>BPH management: minimal to maximal</TI>
<SO>Patient Care</SO>
<YR>1996</YR>
<PG>18-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McConnell-1994" NAME="McConnell 1994" TYPE="BOOK">
<AU>McConnell JD, Barry MJ, Bruskewitz RC, et al</AU>
<SO>Benign prostatic hyperplasia: diagnosis and treatment</SO>
<YR>1994</YR>
<PB>U.S. Department of Health and Human Services. Public Health Service. Agency for Health Care Policy and Research</PB>
<CY>Rockville, Maryland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oesterling-1995" NAME="Oesterling 1995" TYPE="JOURNAL_ARTICLE">
<AU>Oesterling JE</AU>
<TI>Benign prostatic hyperplasia. Medical and minimally invasive treatment options</TI>
<SO>New Engl J Med</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>99-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roos-1998" NAME="Roos 1998" TYPE="JOURNAL_ARTICLE">
<AU>Roos NP, Wennberg JE, Malenka DJ, et al</AU>
<TI>Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia</TI>
<SO>N Engl J Med</SO>
<YR>1998</YR>
<VL>320</VL>
<PG>1120-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz--1995" NAME="Schulz  1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tewari-1999" NAME="Tewari 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tewari A, Oleska J, Johnson C, et al</AU>
<TI>Minimally invasive therapy of benign prostatic hypertrophy</TI>
<SO>Hospital Physician</SO>
<YR>1999</YR>
<VL>68</VL>
<PG>29-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasson-1995" NAME="Wasson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG</AU>
<TI>Comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-02 10:37:38 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hoffman-2003" MODIFIED="2008-06-02 10:37:38 -0500" MODIFIED_BY="[Empty name]" NAME="Hoffman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman RM, MacDonald R, Slaton JW, Wilt TJ</AU>
<TO>Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review</TO>
<SO>J Urol</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>210-15</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-02 10:45:37 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Anson-1995">
<CHAR_METHODS>
<P>NON- CONTACT LASER. <BR/>Tissue effect: coagulation. Subjects blinded: No<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=151 men, &gt;50 yrs old.<BR/>Country/Region: UK<BR/>Mean age: 68 yrs (range 52-84)<BR/>Race: not stated<BR/>Not available to follow-up: 29 (17%).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=76): Urolase fiber -<BR/>Nd-YAG laser - settings; 60 watts, 60 spd x 4, 4 to 9 minutes per session (mps). 2. TURP (n=75).<BR/>Catheter protocol: at MD discretion.<BR/>Routine antibiotics (preop): at MD discretion.<BR/>Mean average of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>American Urological Association (AUA) symptom score; peak urine flow (PUF); residual volume (RV); total voided volume (TVV); hospital length of stay; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: candidates for surgical treatment of Bladder outflow obstruction (BOO) secondary to Benign prostatic hyperplasia (BPH).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carter-1999a">
<CHAR_METHODS>
<P>HYBRID LASER.<BR/>Tissue effect: coagulation and vaporization. <BR/>Subjects blinded: Unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=204 men.<BR/>Country: UK <BR/>Mean age: 67.4 years<BR/>Race: not stated<BR/>Not available to follow-up: 35 (17%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Hybrid laser group (n=101): KTP/Nd:YAG - a. KTP settings; 30 watts. b. Nd:YAG settings; 60 watts.<BR/>2. TURP (n=103):<BR/>Catheter protocol: no<BR/>Routine antibiotics (preop): yes<BR/>Mean average of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IPSS; PUF; prostate size; BPH-11 (symptom improvement); <BR/>QoL (SF 36); tissue resected;<BR/>hospital length of stay; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: "BLUES PROTOCOL" IPSS &gt;12 points; PUF &lt;15 ml/s with a VV &gt;200 ml or PUF &lt;13 (VV 150-200) or PUF &lt;10 (VV 100-150); RV &lt;300 ml; BPH "severe enough to warrant an operative intervention."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Costello-1995">
<CHAR_METHODS>
<P>NON-CONTACT LASER.<BR/>Tissue effect: coagulation. Subjects blinded: No<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=71 "evaluable" men, &gt;50 yrs old.<BR/>Country/Region: Australia<BR/>Mean age: 68 yrs (range 50-88) <BR/>Race: not stated<BR/>Not available to follow-up: "50 patients have completed 6 months of follow-up."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=34): Urolase fiber Nd-YAG laser - settings; 60 watts, 21.7 kJ, 60 spd x 4 for each lobe, 6.5 mps.<BR/>2. TURP (n=37).<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): yes<BR/>Mean average of follow-up: 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; Mean urine flow (MUF); RV; PV; hospital length of stay; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: "symptomatic bladder neck obstruction."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cowles-1995">
<CHAR_METHODS>
<P>NON-CONTACT LASER.<BR/>Tissue effect: coagulation Subjects blinded: No.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=115 men, &gt;50 yrs old. <BR/>Country/Region: USA<BR/>Mean age: 66 yrs<BR/>(range 50-84)<BR/>Race: not stated<BR/>Not available to follow-up: 3 (3%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=56): Urolase fiber Nd-YAG laser settings; 40 watts, 10.2 kJ, 30 spd x 2 for each lobe, 4.2 mps.<BR/>2. TURP (n=59).<BR/>Catheter protocol: unclear<BR/>Routine antibiotics (preop): unclear<BR/>Mean average of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; RV; PV; QoL; global assessment; hospital length of stay; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: "candidates for surgical treatment."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Donovan-2000">
<CHAR_METHODS>
<P>NON-CONTACT LASER. Tissue effect: coagulation<BR/>Subjects blinded: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=340 men.<BR/>Country: UK (multicenter)<BR/>Mean age: 67.0 years<BR/>Race: white <BR/>Not available to follow-up: 8 (2%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Laser group (n=117): Nd-YAG laser settings; 60 watts. 2. TURP (n=117):<BR/>3. CM group (n=106)<BR/>Catheter protocol: no <BR/>Routine antibiotics (preop): yes <BR/>Median follow-up: 7.5 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IPSS; PUF; RV; hospital length of stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: IPSS &gt;8 points; PUF &lt;15 ml/s</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gilling-1998a">
<CHAR_METHODS>
<P>HoLRP STUDY.<BR/>Subjects blinded:<BR/>unclear<BR/>Tissue effect: coagulation vs. resection/ vaporization. IRB/Human subjects approval: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=44 men, &lt;85 yrs old. <BR/>Country/Region: <BR/>USA, New Zealand<BR/>Mean age: 66 yrs (range 44-81).<BR/>Race: not stated<BR/>Not available to follow-up: ?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. HoLRP (n=23): settings; 60 watts, 67 kJ.<BR/>2. VLAP (Coagulation group) (n=21): Nd-YAG laser settings; 60 watts, 53 kJ, 60 spd x 4.<BR/>Catheter protocol: VLAP 5 days, HoLRP 1 day.<BR/>Routine antibiotics (preop): unclear<BR/>Mean average of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; RV; PV; tissue resected; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: AUA &gt;8; PUF&lt;15 ml/s; prostate sizes &lt;100 cm."urodynamically proven BOO."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gilling-1999">
<CHAR_METHODS>
<P>CONTACT LASER. <BR/>Tissue effect: resection/ vaporization.<BR/>Subjects blinded:<BR/>unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=120 men, &lt;80 yrs old.<BR/>Country/Region: <BR/>USA, New Zealand<BR/>Mean age: 67 yrs (range 36-80).<BR/>Race: not stated<BR/>Not available to follow-up: 18 (15%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. HoLRP (n=61):<BR/>Nd-YAG laser settings; 80 watts.<BR/>2. TURP (n=59).<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): unclear <BR/>Mean average of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; RV; PV; QoL; tissue resected; hospital length of stay; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: AUA &gt;/=8**; PUF&lt;/=15 ml/s; RV &lt;400 mls; with prostate sizes &lt;100 cm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gujral-2000">
<CHAR_METHODS>
<P>NON-CONTACT LASER.<BR/>Tissue effect: coagulation. Subjects blinded: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=82 men.<BR/>Country: UK (multicenter)<BR/>Mean age: 70.2 years Race: white <BR/>Not available to follow-up: 2 (2%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=38): Nd-YAG laser, <BR/>2. TURP (n=44)<BR/>Catheter protocol: no <BR/>Routine antibiotics (preop): yes <BR/>Median follow-up: 7 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IPSS; PUF; RV; QoL; Hospital length of stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: IPSS &gt; 8, PUF &lt;10-15 ml/s depending on voided volume). Required acute retention or PVR &gt; 300 ml. Prostate size &lt; 120 ml.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kabalin-1995">
<CHAR_METHODS>
<P>NON-CONTACT LASER.<BR/>Tissue effect: coagulation. Subjects blinded:<BR/>unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=25 men, &gt;50 yrs old.<BR/>Country/Region: USA<BR/>Mean age: 67 yrs<BR/>Race: not stated<BR/>Not available to follow-up: 3 (12%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=13): <BR/>Urolase Nd-YAG laser settings; 40 watts, 11.5 kJ, 30-60 spd &gt;/= 4, &gt;/= 3 mps.<BR/>2. TURP (n=12).<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): yes<BR/>Mean follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; RV; PV; global assessment; tissue resected; rehospitalization/re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>AUA &gt;6, PUF&lt;15 ml/s; "significant voiding symptoms."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Keoghane-2000a">
<CHAR_METHODS>
<P>CONTACT LASER.<BR/>Tissue effect: coagulation and vaporization<BR/>Subjects blinded: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=152 men.<BR/>Country: UK<BR/>Mean age: 70 years<BR/>Race: not stated<BR/>Not available to follow-up: 30 (20%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Contact laser "prototype" (n=76): Nd-YAG laser settings; 31 kJ.<BR/>2. TURP (n=76).<BR/>Catheter protocol: no<BR/>Routine antibiotics (preop):<BR/>yes<BR/>Mean average of follow-up: 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA-7; PUF; PV; Short Form-36 (SF-36) includes BPH Bother Score and global assessment;rehospitalization/ re-operation; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>"all patients referred for surgical treatment of BPH."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 10:44:53 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuntz-2002">
<CHAR_METHODS>
<P>CONTACT LASER. <BR/>Tissue effect: vaporization/resection. Subjects blinded: No.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=120 men. Country: Germany. Mean age: 70.2 years. Race: not stated. Not available to follow-up: 16 (13.3%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. HoLRP (n=60) 80-100W. 2. Open prostatectomy (n=60). <BR/>Catheter protocol: unclear <BR/>Pre-op antibiotics: yes <BR/>Mean follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA, PUF, RV, tissue resected, adverse events, hospital length of stay, reoperations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-02 10:44:53 -0500" MODIFIED_BY="[Empty name]">
<P>Prostate &gt; 100 gm, AUA = 8, PUF = 12 mL/s, RV &gt; 50 ml</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mottet-1999">
<CHAR_METHODS>
<P>CONTACT LASER.<BR/>Tissue effect: resection/ vaporization.|<BR/>Subjects blinded: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=36 nondiabetic men, &gt; 45 yrs old. <BR/>Country/Region: France<BR/>Mean age: 66 yrs (range 50-77)<BR/>Race: not stated<BR/>Not available to follow-up: 16 (44%) at 52 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. HoLRP (n=23):<BR/>Nd-YAG laser settings; 60 watts, 2.4 kJ, 25 spd or 80 watts, 2.6 kJ, 30 spd. Mean energy delivered = 103.6 kJ.<BR/>2. TURP (n=13)<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): not stated.<BR/>Mean average of follow-up:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; Madsen score; PUF; PV; catheter time; operation time; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>AUA &gt;13; PUF &lt;12 ml/s; RV &lt;250 mls; PV &lt;60 grams.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Norby-2002">
<CHAR_METHODS>
<P>INTERSTITIAL LASER COAGULATION.<BR/>Tissue effect: coagulation Subject blinded: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=118 men. Country: Denmark (multicenter). Mean age: 66 years <BR/>Race: Not stated.<BR/>Not available to follow-up: 8 (6.7%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ILC group (n=48); NdYag: 7-20W 2. TUMT (n=46): Prostatron 2.0, 2.5.<BR/>3. TURP/TUIP (n=24). <BR/>Catheter protocol: yes <BR/>Routine antibiotics (pre-op): yes<BR/>Mean follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IPSS, PUF, RV, QOL, hospital length-of-stay, rehospitalization/reoperation, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria: PUF &lt; 12 ml/s, IPSS = 7</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sengor-1996">
<CHAR_METHODS>
<P>NON-CONTACT LASER.<BR/>Tissue effect: coagulation<BR/>Subjects blinded: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=60 men, &gt;50 yrs old.<BR/>Country/Region: Turkey<BR/>Mean age: 64 yrs (range 50-85)<BR/>Race: not stated<BR/>Not available to follow-up: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (n=30):<BR/>Ultraline fiber - Nd-YAG laser settings; 60 watts, 12.5-110 kJ (mean 46.6 kJ), x 4 positions (1 additional if median lobe enlarged)<BR/>2. TURP (n=30)<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): not stated<BR/>Mean average of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; MUF; PV; Hospital length of stay; Catheter time; Operation time; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>PUF&lt;/=15 ml/s; MUF &lt;/=10 ml/s; "significant voiding symptoms causing the patient to request therapy."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shingleton-1998">
<CHAR_METHODS>
<P>CONTACT LASER.<BR/>Subjects blinded:<BR/>Tissue effect:<BR/>vaporization<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=31 men.<BR/>N=31 men.<BR/>Country: USA<BR/>Mean age: 67 years<BR/>(range 48-82)<BR/>Race: not stated<BR/>Not available to follow-up: unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP + KTP (n=11) <BR/>Nd-YAG laser settings; 60 watts, 60 spd.<BR/>KTP; 40 watts.<BR/>2. TVP (n=20):<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): unclear<BR/>Mean average of follow-up: 6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shingleton-1999">
<CHAR_METHODS>
<P>CONTACT STUDY.<BR/>Subjects blinded: Unclear<BR/>Tissue effect: <BR/>vaporization<BR/>IRB/Human subjects approval: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=100 &gt; 45 yrs old.<BR/>Country/Region: USA<BR/>Mean age: 68 yrs<BR/>Race: White 68-76%, Black 24-32%<BR/>Not available to follow-up:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP + KTP BNI (n=50):<BR/>Nd-YAG laser settings; 60 watts, 60 spd.<BR/>KTP; 40 watts.<BR/>2. TURP (n=50):<BR/>Catheter protocol: <BR/>Routine antibiotics (preop): <BR/>Mean average of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; MUF; Prostate size; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>&gt; 45 yrs of age; PUF&lt;/=15 ml/s; failed therapy with alpha-blockers.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Suvakovic-1996">
<CHAR_METHODS>
<P>HYBRID, CONTACT and NON-CONTACT LASERS<BR/>Tissue effect: Coagulation and vaporization<BR/>Subjects blinded: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=40, &gt; 50 yrs old.<BR/>Country/Region: <BR/>UK<BR/>Mean age: 65 yrs<BR/>Race: White</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP (non-contact) side-fire laser (n=10):<BR/>Urolase Nd-YAG laser settings; 60 watts, 60 spd x 4.<BR/>2. Contact laser group (n=10): Urolase Nd-YAG laser settings; 40 watts.<BR/>3. VLAP (non-contact) side-fire laser + debridement (n=10).<BR/>4. TURP (n=10).<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): yes<BR/>Mean average of follow-up: 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; Prostate size; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Inclusion criteria:<BR/>Prostate volume &lt; 40 cc; AUA &gt; 15; PUF&lt;/=15 ml/s; PSA &lt; 2.5 ng/ml.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 10:45:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuhkanen--1999b">
<CHAR_METHODS>
<P>CONTACT LASER.<BR/>Tissue effect: coagulation and vaporization.<BR/>Subjects blinded: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=50<BR/>Country/Region: Finland<BR/>Mean age: 67<BR/>(range 56-77) <BR/>Race: unknown<BR/>Not available to follow-up: 2 (4%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Laser group (contact and vaporization) (n=25 ) Nd-YAG laser settings; 40 watts.<BR/>2. TURP (n=25):<BR/>Catheter protocol: no<BR/>Routine antibiotics (preop): yes <BR/>Mean average of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Danish PSS-1; PUF; RV; Prostate size; Hospital length of stay; Rehospitalization/re-operation; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-02 10:45:02 -0500" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:<BR/>Prostate volume 40-100 cc. Urodynamic evidence of obstruction; voiding detrusor pressure &gt;40 cm H2O or slope detrusor pressure/urine flow &gt;2 cm H20 mL/s.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 10:45:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuhkanen-1999a">
<CHAR_METHODS>
<P>HYBRID LASER.<BR/>Tissue effect: coagulation and vaporization.<BR/>Subjects blinded: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=45<BR/>Country/Region: Finland<BR/>Mean age: 67<BR/>(range 46-78) <BR/>Race: unknown<BR/>Not available to follow-up: 2 (4%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. VLAP Hybrid laser group (n= 21): Nd-YAG laser settings; 40 watts, 56 kj, 90 spd for 75 minutes.<BR/>2. TURP (n=24):<BR/>Catheter protocol: yes<BR/>Routine antibiotics (preop): yes<BR/>Mean average of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Danish PSS-1; PUF; MUF; RV; Prostate size;<BR/>Rehospitalization/re-operation; Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-02 10:45:09 -0500" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:<BR/>Prostate volume &lt; 40 cc. Urodynamic evidence of obstruction; voiding detrusor pressure &gt;40 cm H2O or slope detrusor pressure/urine flow &gt;2 cm H20 mL/s.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Melick-2002">
<CHAR_METHODS>
<P>CONTACT LASER. <BR/>Tissue effect: vaporization. Subjects blinded: No. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=141. Country: Netherlands. Mean age: 65.6 years Race: not stated. <BR/>Not available to follow-up: 6 (4.3%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Contact laser (n=45); NdYag. 2. Electro-vaporization (n=46) 3. TURP (n=50). <BR/>Catheter protocol: no <BR/>Pre-op antibiotics: unclear <BR/>Mean follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IPSS, QOL, PUF, length of stay, re-operations, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>LUTS c/w BPH, Schafer obstruction score = 2.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Melick-2003">
<CHAR_METHODS>
<P>See van Melick 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-02 10:45:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zorn-1999">
<CHAR_METHODS>
<P>CONTACT LASER.<BR/>Tissue effect: vaporization<BR/>Subjects blinded:<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=37 men, &gt;50 years old.<BR/>Country: USA<BR/>Mean age: 70 years <BR/>Race: not stated<BR/>Not available to follow-up: 10 (27%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Contact laser ablation of the prostate [CLAP] (n=26):<BR/>Nd-YAG laser,<BR/>2. TURP (n=12):<BR/>Catheter protocol: no <BR/>Routine antibiotics (preop): no <BR/>Mean follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AUA; PUF; RV; hospital length of stay; catheter time; hematocrit changes; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-02 10:45:26 -0500" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:<BR/>AUA &gt; 12; PUF&lt; 15 mL/s; RV &gt;125 mL/s</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>VLAP=Visual Laser Ablation of the Prostate<BR/>TURP=Transurethral resection of the prostate<BR/>Nd-YAG=neodymium:yttrium-aluminium-garnet-laser<BR/>HoLRP=Holmium laser resection of the prostate<BR/>spd=second pulse duration</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albert-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:42 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser techniques (coagulation vs, Vaporization) with no active control (i.e. TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beerlage-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:43 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser coagulation techniques with no active control (i.e. TURP) or sham arm. Follow-up of de la Rosette 1995.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boon-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser coagulation techniques with no active control (i.e. TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breteau-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser techniques (coagulation vs, Vaporization) with no active control (i.e. TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bryan-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study focusing on treatment options for BPH; no outcomes data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carter-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quality of life data. Follow-up of Carter 1999.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-la-Rosette-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser coagulation techniques with no active control (i.e. TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fraundorfer-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Economic study, follow-up to Gilling 1999.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilling-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-02 10:45:45 -0500" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 laser techniques (coagulation vs, Vaporization) with no active control (i.e. TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gilling-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small sample size and/or high rate of attrition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ichiyanagi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jung-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaplan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No indication of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keoghane-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small sample size and/or high rate of attrition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keoghane-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Economic study, follow-up to Keoghane 2000a</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kollmorgen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Langley-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Follow-up &lt; 6 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsuoka-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No indication of randomization, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McAllister-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small sample size and/or high rate of attrition, follow-up to Anson.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muschter-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Narayan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 laser techniques (coagulation vs. evaporation) with no active control (i.e TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orihuela-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 laser coagulation regimens with no active control (i.e TURP) or sham arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schatzl-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No indication of randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shingleton-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small sample size and/or high rate of attrition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tuhakanen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small sample size and/or high rate of attrition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wada-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No indication of randomization.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Beisland-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-McCullough-1994">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Anson-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Carter-1999a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Costello-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cowles-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Donovan-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gilling-1998a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gilling-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gujral-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kabalin-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Keoghane-2000a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuntz-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mottet-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Norby-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sengor-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shingleton-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shingleton-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Suvakovic-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tuhkanen--1999b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tuhkanen-1999a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zorn-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Melick-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Melick-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Laser vs. TURP: Operating Time (minutes)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Laser</P>
</TH>
<TH>
<P>TURP</P>
</TH>
<TH>
<P>p-value</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Costello</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cowles</P>
</TD>
<TD>
<P>23.4</P>
</TD>
<TD>
<P>45.2</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Donovan</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gujral</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin</P>
</TD>
<TD>
<P>24.2</P>
</TD>
<TD>
<P>58.3</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Sengor</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-Contact)</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>20.1</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilling</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>106</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>&lt; 0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)</P>
</TD>
<TD>
<P>18.9</P>
</TD>
<TD>
<P>20.1</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Contact)</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter</P>
</TD>
<TD>
<P>37.4</P>
</TD>
<TD>
<P>35.7</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)</P>
</TD>
<TD>
<P>13.1</P>
</TD>
<TD>
<P>20.1</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Laser vs. TURP: Hospital lenght of stay (days)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Laser</P>
</TH>
<TH>
<P>TURP</P>
</TH>
<TH>
<P>p-value</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Costello</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Cowles</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Donovan</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>3.9</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Gujral</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sengor</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>5.9</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-contact)</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilling</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>3.1</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>&lt; 0.005</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P>2.9</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Contact)</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>3.7</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Laser vs. TURP: Catheter duration (days)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Laser</P>
</TH>
<TH>
<P>TURP</P>
</TH>
<TH>
<P>p-value</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson</P>
</TD>
<TD>
<P>14.7</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Costello</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cowles</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Donovan</P>
</TD>
<TD>
<P>11.8</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Gujral</P>
</TD>
<TD>
<P>25.5</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin</P>
</TD>
<TD>
<P>4.7</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Sengor</P>
</TD>
<TD>
<P>4.8</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-contact)</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilling</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>1.6</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>&lt;0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Contact)</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>&lt;0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>2.0</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)</P>
</TD>
<TD>
<P>10.6</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)</P>
</TD>
<TD>
<P>1.3</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Laser vs. TURP: Re-operations (%)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Laser</P>
</TH>
<TH>
<P>TURP</P>
</TH>
<TH>
<P>p-value</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>&lt; 0.02</P>
</TD>
</TR>
<TR>
<TD>
<P>Costello</P>
</TD>
<TD>
<P>12.5</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Cowles</P>
</TD>
<TD>
<P>10.9</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Donovan</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gujral</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin</P>
</TD>
<TD>
<P>20.0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Sengor</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-contact)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gilling</P>
</TD>
<TD>
<P>1.9</P>
</TD>
<TD>
<P>8.2</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane</P>
</TD>
<TD>
<P>11.3</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>NS</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" NO="5">
<TITLE>Laser vs. TURP Baseline and Follow-up Urinary Symptom Scores (points)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Mean baseline score</P>
</TH>
<TH>
<P>Mean follow-up/ 6 mo</P>
</TH>
<TH>
<P>Mean follow-up/ 1 yr</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 6<BR/>18.1<BR/>18.2<BR/>
<BR/>
</P>
</TD>
<TD>
<P>
<BR/>7.9<BR/>5.9 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>7.7<BR/>5.1 (p = 0.046)</P>
</TD>
</TR>
<TR>
<TD>
<P>Costello<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>NA<BR/>NA</P>
</TD>
<TD>
<P>
<BR/>9.3<BR/>4.4 (p = 0.01)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Cowles<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 6<BR/>18.7 (6.0) [SD]<BR/>20.8 (4.8)<BR/>
<BR/>
</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
<TD>
<P>
<BR/>9.7<BR/>7.5 (p &lt; 0.04)</P>
</TD>
</TR>
<TR>
<TD>
<P>Donovan<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>IPSS<BR/>19.1 (6.6)<BR/>19.2 (6.7</P>
</TD>
<TD>
<P>7.5 months<BR/>8.3<BR/>6.9 (p = NS)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Gujral<BR/>Laser<BR/>TURP<BR/>
</P>
</TD>
<TD>
<P>IPSS<BR/>20.9 (6.4)<BR/>19.5 (7.2)</P>
</TD>
<TD>
<P>7.5 months<BR/>8.7<BR/>5.3 (p = 0.048)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>20.9 (1.9) [SE]<BR/>18.8 (1.8)</P>
</TD>
<TD>
<P>
<BR/>4.6 (0.7)<BR/>5.7 (1.2) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>4.3 (1.7)<BR/>6.3 (1.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sengor<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>15.7 (5.1)<BR/>18.8 (4.5)</P>
</TD>
<TD>
<P>
<BR/>8.0 (5.7)<BR/>8.5 (3.0) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>15.7 (5.1)<BR/>18.8 (4.5)</P>
</TD>
<TD>
<P>
<BR/>8.0 (5.7)<BR/>8.5 (3.0)</P>
</TD>
<TD>
<P>
<BR/>10.0 (4.9)<BR/> 7.2 (6.1) (p = NS)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilling<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>21.9 (6.2)<BR/>23.0 (5.9)</P>
</TD>
<TD>
<P>
<BR/>3.8 (3.8)<BR/>5.0 (4.5) (p=NS)</P>
</TD>
<TD>
<P>
<BR/>4.2 (6.0)<BR/>4.3 (4.1) (p=NS)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>IPSS<BR/>20.0<BR/>23.7</P>
</TD>
<TD>
<P>
<BR/>6.2<BR/>7.7 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>5.9<BR/>4.7 (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>19.9 (7.7)<BR/>19.4 (6.5)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
<TD>
<P>
<BR/>8.7 (6.5)<BR/>5.8 (5.4) (p = 0.006)</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>22.0 (6.0)<BR/>21.0 (6.0)</P>
</TD>
<TD>
<P>
<BR/>7<BR/>4 (p = 0.01)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>7<BR/>3 (p=0.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>18.0 (6.0)<BR/>18.8 (4.5)</P>
</TD>
<TD>
<P>
<BR/>8.7 (5.4)<BR/>8.5 (3.0) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>8.7 (4.9)<BR/>7.2 (6.1) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>DanPSS-1<BR/>20.0 (11.0)<BR/>21.0 (11.0)</P>
</TD>
<TD>
<P>
<BR/>6.0 (9.0)<BR/>5.0 (7.0) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>24.0<BR/>24.7</P>
</TD>
<TD>
<P>
<BR/>9.1<BR/>8.3 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>8.4<BR/>4.7 (p &lt; 0.05)</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>IPSS<BR/>20.3<BR/>19.8</P>
</TD>
<TD>
<P>
<BR/>6.7<BR/>6.4 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>6.6<BR/>5.9 (p = NS)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>17.0 (6.0)<BR/>19.0 (0.8)</P>
</TD>
<TD>
<P>
<BR/>7.4 (4.3)<BR/>8.5 (3.0) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>DanPSS-1<BR/>18.6<BR/>23.3</P>
</TD>
<TD>
<P>
<BR/>5.5<BR/>4.7 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>AUA 7<BR/>24.2<BR/>24.7</P>
</TD>
<TD>
<P>
<BR/>8.3<BR/>8.2</P>
</TD>
<TD>
<P>
<BR/>13.7<BR/> 4.7 (p &lt; 0.05)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" NO="6">
<TITLE>Laser vs. TURP Baseline and Follow-up Peak Urinary Flow rate (mL/s)</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Mean baseline score</P>
</TH>
<TH>
<P>Mean follow-up/ 6 mo</P>
</TH>
<TH>
<P>Mean follow-up/ 1 yr</P>
</TH>
</TR>
<TR>
<TD>
<P>Anson<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/> 9.5<BR/>10.0</P>
</TD>
<TD>
<P>
<BR/>15.6<BR/>19.9 (p = 0.037)</P>
</TD>
<TD>
<P>
<BR/>15.4<BR/>21.8 (p = 0.009)</P>
</TD>
</TR>
<TR>
<TD>
<P>Costello<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.8<BR/>9.5</P>
</TD>
<TD>
<P>
<BR/>15.8<BR/>19.1 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Cowles<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.9 (3.6) [SD]<BR/>9.5 (3.2)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
<TD>
<P>
<BR/>14.2<BR/>16.5 (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Donovan<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>10.4 (2.9)<BR/>10.3 (2.7)</P>
</TD>
<TD>
<P>7.5 months<BR/>16.2<BR/>20.0 (p &lt; 0.05)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Gujral<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>11.2 (5.3)<BR/> 8.5 (3.6)</P>
</TD>
<TD>
<P>7.5 months<BR/>16.9<BR/>17.0 (p = NS)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Kabalin<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.5 (1.1) [SE]<BR/>9.0 (1.1)</P>
</TD>
<TD>
<P>
<BR/>20.5 (1.8)<BR/>22.9 (2.8)</P>
</TD>
<TD>
<P>
<BR/>21.6 (1.5)<BR/>21.6 (2.2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Sengor<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.7 (2.3)<BR/>8.4 (2.8)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>18.2 (2.1)<BR/>19.8 (2.5)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Non-contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>10.5 (3.7)<BR/>11.1 (6.4)</P>
</TD>
<TD>
<P>
<BR/>16.2 (4.2)<BR/>19.0 (0.8) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>12.6 (3.7)<BR/>15.2 (2.7) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilling<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.9 (3.0)<BR/>9.1 (3.2)</P>
</TD>
<TD>
<P>
<BR/>23.9 (8.7)<BR/>22.4 (9.0) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>25.2 (11.9)<BR/>20.4 (8.5) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Mottet<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.5<BR/>7.7</P>
</TD>
<TD>
<P>
<BR/>17.5<BR/>16.6 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>19.3<BR/>17.6 (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Keoghane<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>11.8 (4.5)<BR/>11.4 (5.0)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA</P>
</TD>
<TD>
<P>
<BR/>17.1 (13.2)<BR/>21.2 (12.4) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Shingleton<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>7.6 (3.4)<BR/>6.5 (4.0)</P>
</TD>
<TD>
<P>
<BR/>15.8 (6.9)<BR/>16.3 (6.4) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>15.4 (4.9)<BR/>16.7 (7.6) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>12.2 (3.8)<BR/>11.1 (6.4)</P>
</TD>
<TD>
<P>
<BR/>18.7 (7.5)<BR/>19.0 (8.0 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>25.3 (5.9)<BR/>15.2 (2.7) (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>9.0 (3.8)<BR/>8.2 (3.2)</P>
</TD>
<TD>
<P>
<BR/>17.9 (7.1)<BR/>21.1 (9.7) (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Contact)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.7<BR/>9.0</P>
</TD>
<TD>
<P>
<BR/>20.0<BR/>23.1 (p = NS)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>20.0<BR/>26.9 (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Carter<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/> 9.5<BR/>10.0</P>
</TD>
<TD>
<P>
<BR/>18.5<BR/>19.0 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>18.0<BR/>19.5 (p = NS)</P>
</TD>
</TR>
<TR>
<TD>
<P>Suvakovic (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>11.8 (4.1)<BR/>11.1 (6.4)<BR/>
</P>
</TD>
<TD>
<P>
<BR/>19.4 (3.4)<BR/>19.0 (0.8)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukhanen (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>8.5<BR/>7.2</P>
</TD>
<TD>
<P>
<BR/>14.4<BR/>19.6 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>NA<BR/>NA<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Zorn (Hybrid)<BR/>Laser<BR/>TURP</P>
</TD>
<TD>
<P>
<BR/>6.2<BR/>9.0</P>
</TD>
<TD>
<P>
<BR/>28.2<BR/>23.1 (p = NS)</P>
</TD>
<TD>
<P>
<BR/>20.5<BR/>26.9</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Non-contact Laser versus TURP</NAME>
<CONT_OUTCOME CHI2="2.080931491620051" CI_END="-0.7035762464281881" CI_START="-4.244152134112556" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.473864190270372" ESTIMABLE="YES" I2="3.889195388986306" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.35329025999273644" P_Q="1.0" P_Z="0.006164055943664203" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.10675687492729145" TOTALS="YES" TOTAL_1="179" TOTAL_2="180" UNITS="" WEIGHT="100.0" Z="2.738924327219798">
<NAME>Mean Change - AUA Symptom Score: &gt; 6 months follow-up</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors laser</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.2465900277307398" CI_START="-7.353409972269262" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="-13.3" MEAN_2="-9.0" ORDER="3497" SD_1="7.5" SD_2="8.9" SE="1.5578908573597112" STUDY_ID="STD-Cowles-1995" TOTAL_1="57" TOTAL_2="55" WEIGHT="32.197533277599085"/>
<CONT_DATA CI_END="0.8378886482952645" CI_START="-3.8378886482952645" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-10.8" ORDER="3498" SD_1="7.46" SD_2="8.75" SE="1.1928222491516334" STUDY_ID="STD-Donovan-2000" TOTAL_1="89" TOTAL_2="96" WEIGHT="53.33581502288135"/>
<CONT_DATA CI_END="2.610093017419822" CI_START="-6.610093017419822" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-14.2" MEAN_2="-12.2" ORDER="3499" SD_1="8.79" SD_2="9.62" SE="2.3521314951619763" STUDY_ID="STD-Gujral-2000" TOTAL_1="33" TOTAL_2="29" WEIGHT="14.466651699519568"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.427367461947858" CI_END="2.698166931452368" CI_START="-2.2802788161661516" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20894405764310828" ESTIMABLE="YES" I2="73.7472343478081" I2_Q="82.54626306038426" ID="CMP-001.02" NO="2" P_CHI2="0.009625809552754938" P_Q="0.016682904812131083" P_Z="0.8693231062748251" Q="5.729432060650822" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.4827293209686765" TOTALS="YES" TOTAL_1="120" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="0.16451834509196042">
<NAME>AUA Symptom Score:</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Laser</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.510083178379064" CI_END="3.973980341301648" CI_START="-5.002625469696939" DF="1.0" EFFECT_SIZE="-0.5143225641976455" ESTIMABLE="YES" I2="81.8514536418636" ID="CMP-001.02.01" NO="1" P_CHI2="0.01890724514721842" P_Z="0.8222937811451331" STUDIES="2" TAU2="8.65988379530917" TOTAL_1="80" TOTAL_2="77" WEIGHT="51.60703163704321" Z="0.22459573774055164">
<NAME>12 months follow-up</NAME>
<CONT_DATA CI_END="-0.7055831162076511" CI_START="-4.49441688379235" EFFECT_SIZE="-2.6000000000000005" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="7.7" ORDER="3500" SD_1="5.5" SD_2="5.8" SE="0.9665569871361249" STUDY_ID="STD-Anson-1995" TOTAL_1="70" TOTAL_2="67" WEIGHT="29.776634958369026"/>
<CONT_DATA CI_END="5.341149402965562" CI_START="-1.341149402965562" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="4.3" ORDER="3501" SD_1="4.1" SD_2="3.5" SE="1.7046993869888027" STUDY_ID="STD-Kabalin-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="21.830396678674177"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.18785222291797152" CI_END="2.974180798418935" CI_START="-0.2797537476988332" DF="1.0" EFFECT_SIZE="1.3472135253600508" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.664710244914209" P_Z="0.10459964000355397" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="48.39296836295679" Z="1.6229521225872703">
<NAME>6 months follow-up</NAME>
<CONT_DATA CI_END="3.267593422565804" CI_START="-0.2675934225658021" EFFECT_SIZE="1.5000000000000009" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="7.8" ORDER="3502" SD_1="4.2" SD_2="2.6" SE="0.9018499505645788" STUDY_ID="STD-Sengor-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="30.456379117243532"/>
<CONT_DATA CI_END="4.662328588822668" CI_START="-3.6623285888226684" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="8.0" ORDER="3503" SD_1="3.0" SD_2="5.7" SE="2.12367605815953" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="9" WEIGHT="17.93658924571326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3068169032456929" CI_END="4.89389966488093" CI_START="1.4656534419243141" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1797765534026223" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.5202694712760187" P_Q="1.0" P_Z="2.770949967035713E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="190" UNITS="" WEIGHT="99.99999999999999" Z="3.6358225857996733">
<NAME>Mean Change - Peak Urine Flow (mL/s): &gt; 6 months follow-up</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors TURP</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.7671837643083705" CI_START="-1.3671837643083697" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="5.3" ORDER="3504" SD_1="9.5" SD_2="6.9" SE="1.5649184314109463" STUDY_ID="STD-Cowles-1995" TOTAL_1="57" TOTAL_2="55" WEIGHT="31.232333091461964"/>
<CONT_DATA CI_END="6.272239198159218" CI_START="1.5277608018407816" EFFECT_SIZE="3.8999999999999995" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="5.8" ORDER="3505" SD_1="9.85" SD_2="6.96" SE="1.2103483619449837" STUDY_ID="STD-Donovan-2000" TOTAL_1="98" TOTAL_2="102" WEIGHT="52.21160761593123"/>
<CONT_DATA CI_END="7.912729015854089" CI_START="-0.5127290158540889" EFFECT_SIZE="3.7" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="5.7" ORDER="3506" SD_1="9.2" SD_2="9.09" SE="2.14939103426571" STUDY_ID="STD-Gujral-2000" TOTAL_1="40" TOTAL_2="33" WEIGHT="16.556059292606793"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.582869450700649" CI_END="4.7488888407277745" CI_START="0.526899625083677" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6378942329057256" ESTIMABLE="YES" I2="54.427168539994454" I2_Q="54.01703044224396" ID="CMP-001.04" NO="4" P_CHI2="0.0864511917621339" P_Q="0.14029528923599244" P_Z="0.014318716282296078" Q="2.174718182878487" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.385530271984224" TOTALS="YES" TOTAL_1="120" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="2.4491666972353388">
<NAME>Peak Urine Flow (mL/s)</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors TURP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.8029397239723446" CI_END="9.716598368204785" CI_START="-2.7835944769467895" DF="1.0" EFFECT_SIZE="3.4665019456289983" ESTIMABLE="YES" I2="73.70455298840619" ID="CMP-001.04.01" NO="1" P_CHI2="0.05116272587286075" P_Z="0.2770110780559969" STUDIES="2" TAU2="15.09469245202559" TOTAL_1="80" TOTAL_2="77" WEIGHT="31.36774335826223" Z="1.0870582638100854">
<NAME>12 months follow-up</NAME>
<CONT_DATA CI_END="10.159707060902157" CI_START="2.6402929390978427" EFFECT_SIZE="6.4" ESTIMABLE="YES" MEAN_1="21.8" MEAN_2="15.4" ORDER="3507" SD_1="14.1" SD_2="7.5" SE="1.9182531365669202" STUDY_ID="STD-Anson-1995" TOTAL_1="70" TOTAL_2="67" WEIGHT="19.1263070318792"/>
<CONT_DATA CI_END="5.219145253854926" CI_START="-5.219145253854926" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="21.6" ORDER="3508" SD_1="6.96" SD_2="4.74" SE="2.662878142161222" STUDY_ID="STD-Kabalin-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.24143632638303"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6052115438498171" CI_END="2.8567753561098694" CI_START="0.7016443693034138" DF="1.0" EFFECT_SIZE="1.7792098627066417" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.4365966400377843" P_Z="0.0012114437344156643" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="68.63225664173777" Z="3.236171975802641">
<NAME>6 months follow-up</NAME>
<CONT_DATA CI_END="2.7683314459604276" CI_START="0.4316685540395755" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="19.8" MEAN_2="18.2" ORDER="3509" SD_1="2.5" SD_2="2.1" SE="0.5960984258772484" STUDY_ID="STD-Sengor-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="42.32438359193346"/>
<CONT_DATA CI_END="5.588388899182629" CI_START="0.011611100817372044" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="16.2" ORDER="3510" SD_1="0.8" SD_2="4.2" SE="1.4226735395022991" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="9" WEIGHT="26.307873049804307"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Contact Laser versus TURP</NAME>
<CONT_OUTCOME CHI2="4.134435637940538" CI_END="0.2570237001147435" CI_START="-2.5427761233615174" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.142876211623387" ESTIMABLE="YES" I2="27.438705963400302" I2_Q="55.93649645931989" ID="CMP-002.01" NO="1" P_CHI2="0.24730876299702909" P_Q="0.13194667591787224" P_Z="0.10957380811793135" Q="2.269451858445129" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5608236269150405" TOTALS="SUB" TOTAL_1="169" TOTAL_2="160" UNITS="" WEIGHT="200.0" Z="1.6001116899766163">
<NAME>AUA (IPSS) Symptom Score:</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Laser</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8649837794954087" CI_END="-0.3457659807016029" CI_START="-3.2151278911151833" DF="2.0" EFFECT_SIZE="-1.7804469359083932" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.39357180887060694" P_Z="0.015002195394199726" STUDIES="3" TAU2="0.0" TOTAL_1="120" TOTAL_2="107" WEIGHT="100.0" Z="2.43232605695401">
<NAME>Nd:YAG or KTP/Nd:YAG Vaporization Technique</NAME>
<CONT_DATA CI_END="-0.6798099202666155" CI_START="-5.1201900797333835" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="8.7" ORDER="3512" SD_1="5.4" SD_2="6.5" SE="1.1327708556105929" STUDY_ID="STD-Keoghane-2000a" TOTAL_1="60" TOTAL_2="53" WEIGHT="40.819088762374115"/>
<CONT_DATA CI_END="3.7879367494575047" CI_START="-4.187936749457503" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="8.7" ORDER="3511" SD_1="3.0" SD_2="5.4" SE="2.0346989949375804" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="9" WEIGHT="16.012115707046657"/>
<CONT_DATA CI_END="0.9315903671008208" CI_START="-3.331590367100821" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="5.8" ORDER="3513" SD_1="4.8" SD_2="5.7" SE="1.087566089945802" STUDY_ID="STD-van-Melick-2003" TOTAL_1="50" TOTAL_2="45" WEIGHT="43.16879553057924"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.081703396253375" CI_START="-1.8817033962533758" DF="0.0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="0.9212152919663829" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.00000000000001" Z="0.09890299366926308">
<NAME>Holmium (Ho):YAG Vaporization Technique</NAME>
<CONT_DATA CI_END="2.081703396253375" CI_START="-1.8817033962533758" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.2" ORDER="3514" SD_1="4.1" SD_2="6.0" SE="1.0110917404017619" STUDY_ID="STD-Gilling-1999" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.060666823595367" CI_END="3.1779390982795133" CI_START="-2.2718100413351014" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4530645284722058" ESTIMABLE="YES" I2="50.301504983015064" I2_Q="87.68825092228931" ID="CMP-002.02" NO="2" P_CHI2="0.07353445822240301" P_Q="0.0043723795879282434" P_Z="0.7445129179065424" Q="8.122322780362792" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.583722099920165" TOTALS="SUB" TOTAL_1="173" TOTAL_2="183" UNITS="" WEIGHT="200.0" Z="0.32588294827124487">
<NAME>Peak Urine Flow (mL/s)</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors TURP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9383440432325756" CI_END="3.762593258058799" CI_START="-0.32356945059315145" DF="4.0" EFFECT_SIZE="1.7195119037328237" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.7470981212788933" P_Z="0.09903335022744886" STUDIES="5" TAU2="0.0" TOTAL_1="124" TOTAL_2="130" WEIGHT="100.0" Z="1.6495581026023716">
<NAME>Nd:YAG or KTP/Nd:YAG Vaporization Technique</NAME>
<CONT_DATA CI_END="9.490955784378063" CI_START="-1.2909557843780668" EFFECT_SIZE="4.099999999999998" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="17.1" ORDER="3515" SD_1="12.4" SD_2="13.2" SE="2.7505381868754917" STUDY_ID="STD-Keoghane-2000a" TOTAL_1="45" TOTAL_2="42" WEIGHT="18.34313809708772"/>
<CONT_DATA CI_END="4.373971296797958" CI_START="-1.77397129679796" EFFECT_SIZE="1.299999999999999" ESTIMABLE="YES" MEAN_1="16.7" MEAN_2="15.4" ORDER="3516" SD_1="7.6" SD_2="5.9" SE="1.5683815218264479" STUDY_ID="STD-Shingleton-1999" TOTAL_1="35" TOTAL_2="43" WEIGHT="29.986447266324024"/>
<CONT_DATA CI_END="5.224933602990269" CI_START="-4.624933602990268" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="18.7" ORDER="3518" SD_1="0.8" SD_2="7.5" SE="2.512767398706056" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="9" WEIGHT="20.272558639390844"/>
<CONT_DATA CI_END="8.043637532027056" CI_START="-1.6436375320270509" EFFECT_SIZE="3.200000000000003" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="17.9" ORDER="3517" SD_1="9.7" SD_2="7.1" SE="2.471289049305522" STUDY_ID="STD-Tuhkanen--1999b" TOTAL_1="23" TOTAL_2="25" WEIGHT="20.631035916744025"/>
<CONT_DATA CI_END="7.037807716877291" CI_START="-9.03780771687729" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="22.0" ORDER="3519" SD_1="8.0" SD_2="11.0" SE="4.100997661323622" STUDY_ID="STD-van-Melick-2002" TOTAL_1="11" TOTAL_2="11" WEIGHT="10.76682008045339"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8089932448919424" CI_START="-8.791006755108059" DF="0.0" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.018410518796205352" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.0" Z="2.35725662798021">
<NAME>Holmium (Ho):YAG Vaporization Technique</NAME>
<CONT_DATA CI_END="-0.8089932448919424" CI_START="-8.791006755108059" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="25.2" ORDER="3520" SD_1="8.5" SD_2="11.9" SE="2.036265353133328" STUDY_ID="STD-Gilling-1999" TOTAL_1="49" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>"Hybrid" Laser versus TURP</NAME>
<CONT_OUTCOME CHI2="4.0197998495803375" CI_END="4.186548446102138" CI_START="-1.127808282088633" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5293700820067524" ESTIMABLE="YES" I2="50.24627904772926" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.13400230337604857" P_Q="1.0" P_Z="0.25928607213625965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.7797397972899502" TOTALS="YES" TOTAL_1="116" TOTAL_2="107" UNITS="" WEIGHT="100.0" Z="1.1280801922330803">
<NAME>Peak Urine Flow (mL/s)</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors TURP</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.2656662381195942" CI_START="-1.2656662381195942" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="19.0" ORDER="3523" SD_1="8.0" SD_2="7.0" SE="1.1559734035884743" STUDY_ID="STD-Carter-1999a" TOTAL_1="85" TOTAL_2="84" WEIGHT="44.65482147192641"/>
<CONT_DATA CI_END="2.9686301899036733" CI_START="-3.7686301899036705" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="19.4" ORDER="3521" SD_1="0.8" SD_2="3.4" SE="1.7187204542915058" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="4" WEIGHT="32.055846717363195"/>
<CONT_DATA CI_END="9.631547787807186" CI_START="0.768452212192817" EFFECT_SIZE="5.200000000000001" ESTIMABLE="YES" MEAN_1="19.6" MEAN_2="14.4" ORDER="3522" SD_1="9.8" SD_2="3.2" SE="2.261035316343906" STUDY_ID="STD-Tuhkanen-1999a" TOTAL_1="21" TOTAL_2="19" WEIGHT="23.28933181071039"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Adverse Events</NAME>
<DICH_OUTCOME CHI2="15.854421271329363" CI_END="3.2306100810454375" CI_START="0.976993906370079" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7765940343925335" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="35" I2="43.2335003216086" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.5092845439448548" LOG_CI_START="-0.01010814502032876" LOG_EFFECT_SIZE="0.24958819946226296" METHOD="MH" NO="1" P_CHI2="0.06998464053528941" P_Q="0.0" P_Z="0.05960875711212587" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.36181235724469196" TOTALS="SUB" TOTAL_1="639" TOTAL_2="642" WEIGHT="400.0" Z="1.8836764255841356">
<NAME>Urinary Tract Infection</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>TURP</GROUP_LABEL_2>
<GRAPH_LABEL_1>&gt; risk TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>&gt; risk laser</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.795338567417715" CI_END="4.867375629886068" CI_START="1.0194846134026603" DF="4.0" EFFECT_SIZE="2.2276028735660955" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="14" I2="16.58566034985938" ID="CMP-004.01.01" LOG_CI_END="0.6872948633365468" LOG_CI_START="0.008380675563157183" LOG_EFFECT_SIZE="0.3478377694498519" NO="1" P_CHI2="0.3089490940389442" P_Z="0.04460584746734034" STUDIES="6" TAU2="0.15000610288231622" TOTAL_1="334" TOTAL_2="344" WEIGHT="100.0" Z="2.0083524924419858">
<NAME>Non-contact Laser versus TURP</NAME>
<DICH_DATA CI_END="8.47724347499619" CI_START="1.8380641652539709" EFFECT_SIZE="3.9473684210526314" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="0.9282546567126747" LOG_CI_START="0.26436066816506737" LOG_EFFECT_SIZE="0.596307662438871" ORDER="3524" O_E="0.0" SE="0.3899746152011091" STUDY_ID="STD-Anson-1995" TOTAL_1="76" TOTAL_2="75" VAR="0.15208020050125312" WEIGHT="43.217753822353664"/>
<DICH_DATA CI_END="5.733197825010764" CI_START="0.051640292708768444" EFFECT_SIZE="0.5441176470588235" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7583969274415681" LOG_CI_START="-1.2870113047200507" LOG_EFFECT_SIZE="-0.26430718863924135" ORDER="3525" O_E="0.0" SE="1.2014829205057769" STUDY_ID="STD-Costello-1995" TOTAL_1="34" TOTAL_2="37" VAR="1.4435612082670908" WEIGHT="12.301765394193136"/>
<DICH_DATA CI_END="29.495403563804405" CI_START="0.33870073261780487" EFFECT_SIZE="3.1607142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4697543426761897" LOG_CI_START="-0.47018386396497736" LOG_EFFECT_SIZE="0.4997852393556062" ORDER="3526" O_E="0.0" SE="1.1395293054300173" STUDY_ID="STD-Cowles-1995" TOTAL_1="56" TOTAL_2="59" VAR="1.2985270379338176" WEIGHT="13.376350712569895"/>
<DICH_DATA CI_END="8.812872693557283" CI_START="0.2553083515713189" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9451174965620472" LOG_CI_START="-0.592934978450685" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="3527" O_E="0.0" SE="0.9034596373050189" STUDY_ID="STD-Donovan-2000" TOTAL_1="117" TOTAL_2="117" VAR="0.8162393162393162" WEIGHT="18.85255337409901"/>
<DICH_DATA CI_END="6.137049686994333" CI_START="0.05461582885860897" EFFECT_SIZE="0.5789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.787959639448199" LOG_CI_START="-1.2626814710374066" LOG_EFFECT_SIZE="-0.23736091579460386" ORDER="3528" O_E="0.0" SE="1.2045567391364522" STUDY_ID="STD-Gujral-2000" TOTAL_1="38" TOTAL_2="44" VAR="1.450956937799043" WEIGHT="12.251576696784296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3529" O_E="0.0" SE="0.0" STUDY_ID="STD-Kabalin-1995" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4674047812791081" CI_END="1.575735287989864" CI_START="0.2834780220516675" DF="2.0" EFFECT_SIZE="0.6683459603501627" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.19748326098270924" LOG_CI_START="-0.5474806061597207" LOG_EFFECT_SIZE="-0.1749986725885058" NO="2" P_CHI2="0.7915975529112623" P_Z="0.35714122355873346" STUDIES="3" TAU2="0.0" TOTAL_1="160" TOTAL_2="172" WEIGHT="100.0" Z="0.920826125249405">
<NAME>Contact Laser versus TURP</NAME>
<DICH_DATA CI_END="2.3203753102365394" CI_START="0.1451405011426817" EFFECT_SIZE="0.580327868852459" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36555823574527635" LOG_CI_START="-0.8382113817152348" LOG_EFFECT_SIZE="-0.2363265729849792" ORDER="3530" O_E="0.0" SE="0.7071002320520122" STUDY_ID="STD-Gilling-1999" TOTAL_1="61" TOTAL_2="59" VAR="0.4999907381680096" WEIGHT="37.89682317711022"/>
<DICH_DATA CI_END="3.630358669101223" CI_START="0.041658299271756544" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5599495342142169" LOG_CI_START="-1.3802984643923155" LOG_EFFECT_SIZE="-0.4101744650890492" ORDER="3531" O_E="0.0" SE="1.1397112787639678" STUDY_ID="STD-Keoghane-2000a" TOTAL_1="54" TOTAL_2="63" VAR="1.2989417989417988" WEIGHT="19.665523279698455"/>
<DICH_DATA CI_END="3.1074441691035064" CI_START="0.25426794941196734" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4924033344920937" LOG_CI_START="-0.5947083793868564" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="3532" O_E="0.0" SE="0.6385748020222672" STUDY_ID="STD-van-Melick-2003" TOTAL_1="45" TOTAL_2="50" VAR="0.4077777777777778" WEIGHT="42.437653543191324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0887975632101304E-31" CI_END="9.606408788278554" CI_START="1.4304341472524102" DF="0.0" EFFECT_SIZE="3.7069306930693067" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="100.0" ID="CMP-004.01.03" LOG_CI_END="0.9825610635351122" LOG_CI_START="0.1554678690317379" LOG_EFFECT_SIZE="0.569014466283425" NO="3" P_CHI2="0.0" P_Z="0.007001164413804953" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="104" WEIGHT="100.0" Z="2.696788869765617">
<NAME>"Hybrid" Laser versus TURP</NAME>
<DICH_DATA CI_END="9.606408788278554" CI_START="1.4304341472524102" EFFECT_SIZE="3.706930693069307" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.9825610635351122" LOG_CI_START="0.1554678690317379" LOG_EFFECT_SIZE="0.5690144662834251" ORDER="3533" O_E="0.0" SE="0.48583863662862486" STUDY_ID="STD-Carter-1999a" TOTAL_1="101" TOTAL_2="104" VAR="0.23603918084116102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.216981924590986" CI_START="1.5321198224780552" DF="0.0" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="1.1211322960621328" LOG_CI_START="0.1852927314885546" LOG_EFFECT_SIZE="0.6532125137753437" NO="4" P_CHI2="1.0" P_Z="0.006217306425915289" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="22" WEIGHT="100.0" Z="2.7360950524332943">
<NAME>Interstitial Laser versus TURP</NAME>
<DICH_DATA CI_END="13.216981924590986" CI_START="1.5321198224780552" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.1211322960621328" LOG_CI_START="0.1852927314885546" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="3534" O_E="0.0" SE="0.5497167927110761" STUDY_ID="STD-Norby-2002" TOTAL_1="44" TOTAL_2="22" VAR="0.3021885521885522" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.532886828881795" CI_END="3.8814774148269064" CI_START="1.5003745959143124" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.413228150801629" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.5889970634751966" LOG_CI_START="0.1761997021411521" LOG_EFFECT_SIZE="0.3825983828081744" METHOD="MH" NO="2" P_CHI2="0.47907717351498547" P_Q="0.0" P_Z="2.799732857440936E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="470" TOTAL_2="456" WEIGHT="400.0" Z="3.6331581598481786">
<NAME>Urinary Retention</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>TURP</GROUP_LABEL_2>
<GRAPH_LABEL_1>&gt; risk TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>&gt; risk laser</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.011612645323636097" CI_END="8.582879270675459" CI_START="1.4518232874681947" DF="1.0" EFFECT_SIZE="3.529989234926173" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.9336330036529441" LOG_CI_START="0.1619137582732454" LOG_EFFECT_SIZE="0.5477733809630947" NO="1" P_CHI2="0.9141845004048619" P_Z="0.0053958368528986824" STUDIES="4" TAU2="0.0" TOTAL_1="155" TOTAL_2="156" WEIGHT="100.00000000000001" Z="2.7824007365506795">
<NAME>Non-contact Laser versus TURP</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3535" O_E="0.0" SE="0.0" STUDY_ID="STD-Anson-1995" TOTAL_1="76" TOTAL_2="75" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.057753516214062" CI_START="1.416658934912481" EFFECT_SIZE="3.5821428571428573" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.9570204982850485" LOG_CI_START="0.15126530507134928" LOG_EFFECT_SIZE="0.5541429016781989" ORDER="3536" O_E="0.0" SE="0.47330458904625994" STUDY_ID="STD-Cowles-1995" TOTAL_1="56" TOTAL_2="59" VAR="0.224017234012249" WEIGHT="91.73022005289862"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3537" O_E="0.0" SE="0.0" STUDY_ID="STD-Kabalin-1995" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="3538" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Suvakovic-1996" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="8.269779947101396"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.513065438989053" CI_END="5.724750422881291" CI_START="0.6767803902973768" DF="3.0" EFFECT_SIZE="1.9683492641176956" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="45.58381297664918" ID="CMP-004.02.02" LOG_CI_END="0.7577565578541748" LOG_CI_START="-0.1695522334634491" LOG_EFFECT_SIZE="0.2941021621953629" NO="2" P_CHI2="0.13785934266766153" P_Z="0.21378264475860997" STUDIES="4" TAU2="0.5213576426910078" TOTAL_1="170" TOTAL_2="174" WEIGHT="100.0" Z="1.2432312754400034">
<NAME>Contact Laser versus TURP</NAME>
<DICH_DATA CI_END="5.288711702307383" CI_START="1.162148308902826" EFFECT_SIZE="2.4791666666666665" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.7233498934493876" LOG_CI_START="0.06526155458449946" LOG_EFFECT_SIZE="0.3943057240169435" ORDER="3539" O_E="0.0" SE="0.38656434783905036" STUDY_ID="STD-Keoghane-2000a" TOTAL_1="54" TOTAL_2="63" VAR="0.14943199502023033" WEIGHT="68.10626168833763"/>
<DICH_DATA CI_END="27.87074815972714" CI_START="0.32291921079481023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445148627029772" LOG_CI_START="-0.4909061175904472" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="3540" O_E="0.0" SE="1.1372481406154653" STUDY_ID="STD-Shingleton-1999" TOTAL_1="50" TOTAL_2="50" VAR="1.2933333333333332" WEIGHT="7.869011255766628"/>
<DICH_DATA CI_END="214.55696649939455" CI_START="0.6932141816401456" EFFECT_SIZE="12.195652173913043" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3315426203048437" LOG_CI_START="-0.15913256115566932" LOG_EFFECT_SIZE="1.0862050295745873" ORDER="3542" O_E="0.0" SE="1.4630349306308938" STUDY_ID="STD-van-Melick-2003" TOTAL_1="45" TOTAL_2="50" VAR="2.140471208246144" WEIGHT="4.754679492183963"/>
<DICH_DATA CI_END="2.176548153480647" CI_START="0.126060347801076" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.33776827983690094" LOG_CI_START="-0.8994214989882894" LOG_EFFECT_SIZE="-0.28082660957569416" ORDER="3541" O_E="0.0" SE="0.7267314002700916" STUDY_ID="STD-Zorn-1999" TOTAL_1="21" TOTAL_2="11" VAR="0.5281385281385281" WEIGHT="19.270047563711785"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.966426757073323" CI_START="0.5110738230465689" DF="0.0" EFFECT_SIZE="2.5742574257425743" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="1.1128203112042638" LOG_CI_START="-0.2915163628279129" LOG_EFFECT_SIZE="0.4106519741881754" NO="3" P_CHI2="1.0" P_Z="0.2516901987874067" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="104" WEIGHT="100.0" Z="1.1462537359764977">
<NAME>"Hybrid" Laser versus TURP</NAME>
<DICH_DATA CI_END="12.966426757073323" CI_START="0.5110738230465689" EFFECT_SIZE="2.5742574257425743" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1128203112042638" LOG_CI_START="-0.2915163628279129" LOG_EFFECT_SIZE="0.4106519741881754" ORDER="3543" O_E="0.0" SE="0.8249143139051507" STUDY_ID="STD-Carter-1999a" TOTAL_1="101" TOTAL_2="104" VAR="0.6804836252856055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.84161099669075" CI_START="0.23750697013403116" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="1.2263836319088486" LOG_CI_START="-0.624323640580886" LOG_EFFECT_SIZE="0.3010299956639812" NO="4" P_CHI2="1.0" P_Z="0.5237323605289996" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="22" WEIGHT="100.0" Z="0.6376026706524162">
<NAME>Interstitial Laser versus TURP</NAME>
<DICH_DATA CI_END="16.84161099669075" CI_START="0.23750697013403116" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2263836319088486" LOG_CI_START="-0.624323640580886" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="3544" O_E="0.0" SE="1.087114613009218" STUDY_ID="STD-Norby-2002" TOTAL_1="44" TOTAL_2="22" VAR="1.1818181818181819" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="101.36680666857083" CI_END="5.426694811441461" CI_START="0.8893173554829039" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1968281404615877" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="62" I2="91.1213539266099" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.7345353982454409" LOG_CI_START="-0.05094323212276254" LOG_EFFECT_SIZE="0.34179608306133924" METHOD="MH" NO="3" P_CHI2="9.992007221626409E-16" P_Q="0.0" P_Z="0.08805799106874103" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.6815028798070033" TOTALS="SUB" TOTAL_1="238" TOTAL_2="215" WEIGHT="400.0" Z="1.7057319880059818">
<NAME>Retrograde ejaculation</NAME>
<GROUP_LABEL_1>TURP</GROUP_LABEL_1>
<GROUP_LABEL_2>Laser</GROUP_LABEL_2>
<GRAPH_LABEL_1>&gt; risk laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>&gt; risk TURP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="34.487841046636035" CI_END="45.93388908808782" CI_START="0.5105933422148536" DF="3.0" EFFECT_SIZE="4.8428852918908945" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="19" I2="91.30128210709606" ID="CMP-004.03.01" LOG_CI_END="1.662133217418629" LOG_CI_START="-0.2919248523954619" LOG_EFFECT_SIZE="0.6851041825115836" NO="1" P_CHI2="1.562878858551997E-7" P_Z="0.1693331557620775" STUDIES="4" TAU2="4.6765748631757145" TOTAL_1="78" TOTAL_2="82" WEIGHT="100.0" Z="1.374349661479827">
<NAME>Non-contact Laser versus TURP</NAME>
<DICH_DATA CI_END="0.9883783376671205" CI_START="0.28778903139036976" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="-0.005076781617519845" LOG_CI_START="-0.5409257625099555" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="3545" O_E="0.0" SE="0.31476034387145096" STUDY_ID="STD-Anson-1995" TOTAL_1="27" TOTAL_2="24" VAR="0.09907407407407406" WEIGHT="31.44992490955701"/>
<DICH_DATA CI_END="22.35262192229623" CI_START="1.514419193734747" EFFECT_SIZE="5.818181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.3493284724164871" LOG_CI_START="0.18024610523483706" LOG_EFFECT_SIZE="0.7647872888256622" ORDER="3546" O_E="0.0" SE="0.6867247695335512" STUDY_ID="STD-Costello-1995" TOTAL_1="11" TOTAL_2="16" VAR="0.47159090909090906" WEIGHT="26.008626184329582"/>
<DICH_DATA CI_END="71.33644820086211" CI_START="1.6350687894016898" EFFECT_SIZE="10.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.8533114822778256" LOG_CI_START="0.2135360286960737" LOG_EFFECT_SIZE="1.0334237554869496" ORDER="3547" O_E="0.0" SE="0.9632122184533259" STUDY_ID="STD-Kabalin-1995" TOTAL_1="10" TOTAL_2="12" VAR="0.9277777777777777" WEIGHT="21.46147495957058"/>
<DICH_DATA CI_END="166.2284751592905" CI_START="3.465110291410908" EFFECT_SIZE="24.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" LOG_CI_END="2.2207054210442583" LOG_CI_START="0.539717062378954" LOG_EFFECT_SIZE="1.380211241711606" ORDER="3548" O_E="0.0" SE="0.9874208829065749" STUDY_ID="STD-Sengor-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.975" WEIGHT="21.079973946542832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.375820767215785" CI_END="6.9412429452018065" CI_START="0.35790352920858526" DF="3.0" EFFECT_SIZE="1.576164758894806" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="33" I2="87.16622603383641" ID="CMP-004.03.02" LOG_CI_END="0.8414372450815257" LOG_CI_START="-0.4462340191057846" LOG_EFFECT_SIZE="0.19760161298787066" NO="2" P_CHI2="3.371641802507597E-5" P_Z="0.5474812514689205" STUDIES="4" TAU2="1.817281750168666" TOTAL_1="110" TOTAL_2="103" WEIGHT="100.0" Z="0.6015386931658848">
<NAME>Contact Laser versus TURP</NAME>
<DICH_DATA CI_END="1.0471324586957398" CI_START="0.7750905117151794" EFFECT_SIZE="0.9009009009009009" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="24" LOG_CI_END="0.020001621929138094" LOG_CI_START="-0.11064757950245292" LOG_EFFECT_SIZE="-0.04532297878665743" ORDER="3549" O_E="0.0" SE="0.0767439876448939" STUDY_ID="STD-Gilling-1999" TOTAL_1="37" TOTAL_2="25" VAR="0.005889639639639628" WEIGHT="31.821412226764274"/>
<DICH_DATA CI_END="2.3903408877646037" CI_START="0.30735945710157286" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3784598403281286" LOG_CI_START="-0.5123534195893551" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="3550" O_E="0.0" SE="0.5232681184722836" STUDY_ID="STD-Mottet-1999" TOTAL_1="7" TOTAL_2="12" VAR="0.27380952380952384" WEIGHT="27.461193848285234"/>
<DICH_DATA CI_END="6.823446325509919" CI_START="0.14655350863704047" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8340037796584007" LOG_CI_START="-0.8340037796584007" LOG_EFFECT_SIZE="0.0" ORDER="3551" O_E="0.0" SE="0.9797958971132712" STUDY_ID="STD-Shingleton-1999" TOTAL_1="50" TOTAL_2="50" VAR="0.96" WEIGHT="20.327523910779583"/>
<DICH_DATA CI_END="87.98958956216127" CI_START="1.920681762932966" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.9444312918870055" LOG_CI_START="0.28345541272666797" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="3552" O_E="0.0" SE="0.9756654533819863" STUDY_ID="STD-Tuhkanen-1999a" TOTAL_1="16" TOTAL_2="16" VAR="0.9519230769230769" WEIGHT="20.389870014170906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.976362087296185" CI_START="0.8915231070611571" DF="0.0" EFFECT_SIZE="2.666666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.9018048605675668" LOG_CI_START="-0.049867396023004405" LOG_EFFECT_SIZE="0.42596873227228116" NO="3" P_CHI2="1.0" P_Z="0.07933447741753269" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="16" WEIGHT="100.0" Z="1.7545607072436484">
<NAME>"Hybrid" Laser versus TURP</NAME>
<DICH_DATA CI_END="7.976362087296185" CI_START="0.891523107061157" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.9018048605675668" LOG_CI_START="-0.04986739602300446" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="3553" O_E="0.0" SE="0.5590169943749473" STUDY_ID="STD-Tuhkanen--1999b" TOTAL_1="24" TOTAL_2="16" VAR="0.31249999999999994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4567836654336312" CI_START="0.329005570422658" DF="0.0" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="0.1633950631741441" LOG_CI_START="-0.4827967489091678" LOG_EFFECT_SIZE="-0.1597008428675119" NO="4" P_CHI2="1.0" P_Z="0.33265644941455774" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="14" WEIGHT="100.0" Z="0.9687770549486889">
<NAME>Interstitial Laser versus TURP</NAME>
<DICH_DATA CI_END="1.4567836654336312" CI_START="0.329005570422658" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.1633950631741441" LOG_CI_START="-0.4827967489091678" LOG_EFFECT_SIZE="-0.1597008428675119" ORDER="3554" O_E="0.0" SE="0.3795762691187952" STUDY_ID="STD-Norby-2002" TOTAL_1="26" TOTAL_2="14" VAR="0.14407814407814407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.996398753191375" CI_END="7.247720097161992" CI_START="0.7431592596978942" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.320821040473491" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="34" I2="81.24577883880593" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.8602014127861297" LOG_CI_START="-0.12891810656737954" LOG_EFFECT_SIZE="0.36564165310937513" METHOD="MH" NO="4" P_CHI2="0.0011359178315849539" P_Q="0.0" P_Z="0.14732212263246594" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9734460482424598" TOTALS="SUB" TOTAL_1="280" TOTAL_2="287" WEIGHT="200.0" Z="1.4490553615006276">
<NAME>Irritative symptoms/Dysuria</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>TURP</GROUP_LABEL_2>
<GRAPH_LABEL_1>&gt; risk TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>&gt; risk laser</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.232327862104761" CI_END="13.11756190681893" CI_START="1.0015007297482452" DF="2.0" EFFECT_SIZE="3.624534152439033" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="12" I2="67.9092620887155" ID="CMP-004.04.01" LOG_CI_END="1.117853122477879" LOG_CI_START="6.512700804393809E-4" LOG_EFFECT_SIZE="0.559252196279159" NO="1" P_CHI2="0.044326920720055396" P_Z="0.04973349038576634" STUDIES="4" TAU2="0.7998954076878977" TOTAL_1="179" TOTAL_2="183" WEIGHT="99.99999999999999" Z="1.9622490969378372">
<NAME>Non-contact Laser versus TURP</NAME>
<DICH_DATA CI_END="9.44814626512735" CI_START="1.7894775360346378" EFFECT_SIZE="4.1118421052631575" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="6" LOG_CI_END="0.97534660789568" LOG_CI_START="0.2527262509029254" LOG_EFFECT_SIZE="0.6140364293993026" ORDER="3555" O_E="0.0" SE="0.4244707747260007" STUDY_ID="STD-Anson-1995" TOTAL_1="76" TOTAL_2="75" VAR="0.18017543859649124" WEIGHT="43.03266031616452"/>
<DICH_DATA CI_END="508.30418293097" CI_START="1.9503089633560262" EFFECT_SIZE="31.485714285714284" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.7061236836085936" LOG_CI_START="0.2901034167223876" LOG_EFFECT_SIZE="1.4981135501654905" ORDER="3556" O_E="0.0" SE="1.4191822642621585" STUDY_ID="STD-Costello-1995" TOTAL_1="34" TOTAL_2="37" VAR="2.014078299196267" WEIGHT="16.61690276068534"/>
<DICH_DATA CI_END="3.7931806840755597" CI_START="0.5202378092229538" EFFECT_SIZE="1.4047619047619047" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.579003530345299" LOG_CI_START="-0.28379808785681154" LOG_EFFECT_SIZE="0.1476027212442437" ORDER="3557" O_E="0.0" SE="0.5068139414688105" STUDY_ID="STD-Cowles-1995" TOTAL_1="56" TOTAL_2="59" VAR="0.2568603712671509" WEIGHT="40.35043692315014"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3558" O_E="0.0" SE="0.0" STUDY_ID="STD-Kabalin-1995" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4741958928457757" CI_START="0.4814690586837946" DF="0.0" EFFECT_SIZE="0.8424842484248425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.16855519690788362" LOG_CI_START="-0.3174316173134084" LOG_EFFECT_SIZE="-0.07443821020276238" NO="2" P_CHI2="1.0" P_Z="0.5482315487867772" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="104" WEIGHT="100.0" Z="0.6004122202566716">
<NAME>"Hybrid" Laser versus TURP</NAME>
<DICH_DATA CI_END="1.4741958928457757" CI_START="0.4814690586837946" EFFECT_SIZE="0.8424842484248425" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.16855519690788362" LOG_CI_START="-0.3174316173134084" LOG_EFFECT_SIZE="-0.07443821020276238" ORDER="3559" O_E="0.0" SE="0.28547106034711556" STUDY_ID="STD-Carter-1999a" TOTAL_1="101" TOTAL_2="104" VAR="0.0814937262957065" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5358662170143248" CI_END="2.768582988907966" CI_START="0.3941812260232667" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0446642699522666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.4422575461194369" LOG_CI_START="-0.4043040640460747" LOG_EFFECT_SIZE="0.01897674103668106" METHOD="MH" NO="5" P_CHI2="0.7649589642018396" P_Q="0.0" P_Z="0.9299799170752213" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="187" TOTAL_2="180" WEIGHT="200.0" Z="0.08787010544587885">
<NAME>Erectile Dysfunction</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>TURP</GROUP_LABEL_2>
<GRAPH_LABEL_1>&gt; risk TURP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>&gt; risk laser</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.107346024645778" CI_START="0.27423232764198513" DF="0.0" EFFECT_SIZE="1.5803571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.9593918374805782" LOG_CI_START="-0.5618813500973281" LOG_EFFECT_SIZE="0.198755243691625" NO="1" P_CHI2="1.0" P_Z="0.6085523948184264" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="108" WEIGHT="99.99999999999999" Z="0.5121409126973354">
<NAME>Non-contact Laser versus TURP</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3560" O_E="0.0" SE="0.0" STUDY_ID="STD-Costello-1995" TOTAL_1="34" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.107346024645778" CI_START="0.27423232764198513" EFFECT_SIZE="1.5803571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9593918374805782" LOG_CI_START="-0.5618813500973281" LOG_EFFECT_SIZE="0.198755243691625" ORDER="3561" O_E="0.0" SE="0.8936034008069897" STUDY_ID="STD-Cowles-1995" TOTAL_1="56" TOTAL_2="59" VAR="0.7985270379338175" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3562" O_E="0.0" SE="0.0" STUDY_ID="STD-Kabalin-1995" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2249482818895545" CI_END="2.804010378267252" CI_START="0.26846083355186307" DF="1.0" EFFECT_SIZE="0.8676214401671396" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.44777961671825095" LOG_CI_START="-0.5711190656926983" LOG_EFFECT_SIZE="-0.061669724487223646" NO="2" P_CHI2="0.6352951867972283" P_Z="0.8124573937338517" STUDIES="2" TAU2="0.0" TOTAL_1="84" TOTAL_2="72" WEIGHT="100.0" Z="0.23725703255491296">
<NAME>Contact Laser versus TURP</NAME>
<DICH_DATA CI_END="2.7419169130073904" CI_START="0.2183584670801708" EFFECT_SIZE="0.7737704918032787" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4380542904355784" LOG_CI_START="-0.6608299631889369" LOG_EFFECT_SIZE="-0.11138783637667925" ORDER="3563" O_E="0.0" SE="0.6454900501438239" STUDY_ID="STD-Gilling-1999" TOTAL_1="61" TOTAL_2="59" VAR="0.4166574048346763" WEIGHT="85.97221196735623"/>
<DICH_DATA CI_END="40.109702416314335" CI_START="0.07635309701909805" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.60324943985669" LOG_CI_START="-1.1171733424841013" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="3564" O_E="0.0" SE="1.5979898086569353" STUDY_ID="STD-Mottet-1999" TOTAL_1="23" TOTAL_2="13" VAR="2.5535714285714284" WEIGHT="14.027788032643771"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>